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ABSTRACT
NOTCH1 MODULATION OF LYMPHOID TARGET GENES

SEPTEMBER 2009

OK HYUN CHO, B.A., KOREA UNIVERSITY, REPUBLIC OF KOREA
M.A., KOREA UNIVERSITY, REPUBLIC OF KOREA
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Professor Barbara A. Osborne

Over the past decades, information has accumulated concerning the mechanism
how an exterior signal induced by ligand on neighboring cells is transmitted to the
nucleus through the Notch receptor and the cellular effects of Notch signaling on the
regulation of differentiation, proliferation and apoptosis in many cell types. However,
the function and the mechanism of Notch signaling in peripheral T cells still remains to
be addressed. Therefore, we asked whether Notch1 is involved in CD8+ cytolytic
effector T cell (CTLs) maturation and effector functions and how Notch1 exerts its
cellular function in the nucleus and in the cytoplasm.
The maturation of naïve CD8+ T cells into CTLs is a critical feature of a
functional adaptive immune system. Development of CTLs depends, in part, upon the
expression of the transcriptional regulator, Eomesodermin (EOMES), which is thought
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to regulate the expression of two key effector molecules, perforin and granzyme B. In
addition, the data from previous studies in our lab showed that Notch signaling results
in the activation of NF-κB, IFN-γ secretion and cell proliferation both in CD4+ and
CD8+ T cells. Therefore, we hypothesized that Notch1 may be involved in CD8+ T cell
maturation and effector function. We observed that Notch1 regulates the expression of
EOMES, perforin and granzyme B through direct binding to the promoters of these
crucial effector molecules. By abrogating Notch signaling, both biochemically as well
as genetically, we conclude that Notch activity mediates CTL development through
direct regulation of EOMES, perforin and granzyme B. We further investigated the
molecular steps leading to the formation of intracellular Notch1 (N1ICD)/CSL (also
known as CBF1/RBP-Jκ in mammals; Suppressor of Hairless in Drosophila; and Lag-1
in C. elegans) with other co-factors in target promoters of Notch1 signaling. We
proposed that the association of two nuclear complexes with N1ICD controls the
transcription of genes, allowing the development of effector CTL in the immune system.
Recent studies proposed a model where Notch1 colocalizes with CD4, a
component of the immune synapse, upon T cell stimulation and directly associates with
p56Lck and CD28, as well as PI3K. However, the link between Notch and the TCR
signalosome needed further investigation. We found that Notch1 functions as a scaffold,
associated with the cytosolic components, Carma1, Bcl10, PKCθ and the IKK complex
upon TCR stimulation, leading to the activation of NF-κB and IL-2 production. We
further showed that the N-terminal region of N1ICD is essential for interaction with
Carma1 and that deficiency of Notch1 abolishes the nuclear binding of NF-κB on the il2 promoter, leading to reduced IL-2 production.
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CHAPTER 1
INTRODUCTIONS
1.1 Notch origin
Evolutionally-conserved Notch proteins play an important role in deciding cell
fate from insects to mammals. Notch nomenclature originated from the notched wing of
Drosophila (Figure 1.1) which expressed the haploinsufficient Notch (ArtavanisTsakonas et al., 1999; Poulson, 1937). In a t(7;9)(q34;q34.3) chromosomal
translocation from a case of human T lymphoblastic leukemia (T-ALL), Ellisen et al.
(1991) found that the locus on chromosome 9 contains a gene, Notch1, highly
homologous to the Drosophila gene, Notch. Transcripts of the human gene named
translocation-associated Notch homologue (TAN-1) and its murine counterpart is
ubiquitously expressed both in normal human fetal and adult mouse tissues, but are
most abundant in lymphoid tissues (Ellisen et al., 1991). In addition to Notch1, Notch2
and 3 have been identified at positions 1p13-p11 and 19p13.2-p13.1, respectively,
which are regions of neoplasia-associated translocation (Larsson et al., 1994). Notch4
also has been found primarily in endothelial cells in embryonic and adult life,
suggesting a specific role for Notch4 during development of vertebrate endothelium
(Uyttendaele et al., 1996).
As single-pass transmembrane receptors, Notch receptors bind appropriate
ligands on the neighboring cells that trigger Notch signaling to regulate several
intracellular events. The canonical DSL (Delta, Serrate, Lag-2) ligands of Notch
receptor rely on the pivotal role of Notch signaling effect. However, the ligand binding
to Notch receptor exerts various effects in a positive or negative way depending upon
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cellular context and tissue specificity (D'Souza et al., 2008). The canonical DSL ligands
are type 1 single-pass cell-surface proteins, and share similar structure with extracellular
domains of Notch receptor (Figure 1.2). The multiple tandem epidermal growth factor
(EGF) repeats both on Notch receptors and their ligands are required for binding
between ligand and receptor (Parks et al., 2006; Shimizu et al., 1999). Based on
structural homology of two Drosophila ligands, Delta and Serrate, the mammalian
canonical ligands are named as either Delta-like (Dll1, Dll3 and Dll4) or Serrate-like
(Bray, 2006; Fiuza and Arias, 2007). In vertebrates, there are two types of Serrate-like
ligands, Jagged1 and Jagged2, which have almost twice the number of EGF repeats as
Delta-like ligands (D'Souza et al., 2008). Numerous studies indicate that distinct Notch
ligands can have differential effects of Notch signaling and thus cell-fate decisions in
lymphopoiesis (Allman et al., 2002).

1.2 Canonical Notch signaling
Notch is a heterodimeric transmembrane receptor of 300 kilodaltons (kDa)
composed of an extracellular domain and an intracellular signaling portion, NICD. The
extracellular domain has EGF-like repeats and specific cystein-rich Lin12-Notch (LN)
repeats, while NICD contains recombination signal-binding protein for the CSLassociated molecule (RAM), ankyrin (ANK), nuclear localization sequences (NLS) and
a degradation motif (PEST) (Osborne and Minter, 2007). In mice and humans, four
Notch receptors (Notch1-4) and at least five ligands (Delta-like1, 3 and 4, and Jagged1
and 2) have been identified (Osborne and Minter, 2007). Of the four homologs, Notch1
is most closely related to Drosophila Notch (D-Notch) and acts as an instructive
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transcriptional regulator of T cell vs. non-T cell commitment and of peripheral T cell
differentiation (Allman et al., 2002; Garcia-Peydro et al., 2006; Maillard et al., 2005).
Notch signaling is initiated upon ligand binding to the Notch receptor (Figure 1.3).
Interaction of the extracellular domain of Notch and appropriate ligands on neighboring
cells triggers two sequential cleavages by a metalloprotease and γ-secretase (Maillard et
al., 2005). The immature form of Notch receptor (pre-Notch), which is synthesized as a
single protein in the endoplasmic reticulum (ER), is transported and further processed
by a furin-like protease at the S1 site in the Golgi apparatus to generate a heterodimeric
protein, then displayed in the plasma membrane. The metalloprotease cleaves the
extracellular domain of Notch at the S2 site and then γ-secretase frees NICD from
transmembrane portion (NTM) at the S3 site either in the transmembrane or after
endocytosis.
γ-secretase is a protease that catalyzes intramembrane cleavage of an expanding
list of type 1 transmembrane protein substrates (Kopan and Ilagan, 2004). In fact, the
academic and industrial communities have studied its importance in the pathogenesis of
Alzheimer’s disease (AD) (Borchelt et al., 1996; Tanzi et al., 1996) but it is also known
to cleave and activate Notch (De Strooper et al., 1999; Fortini, 2002; Wolfe, 2001).
Final proteolytic cleavage releases NICD from NTM, and its migration into the nucleus
allows it to regulate downstream targets (Osborne and Minter, 2007). The nuclear
association of NICD with the DNA-binding repressor protein known as CSL (CBF1/RBP-Jκ, mammals; Suppressor of Hairless, Drosophila; and Lag-1, C. elegans)
results in the activation of CSL-repressed genes through the Notch-mediated conversion
of CSL from a repressor into an activator of transcription, leading to the regulation of
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downstream target transcription (Allman et al., 2002; Artavanis-Tsakonas et al., 1999;
Osborne and Miele, 1999). We have defined several critical functions for Notch in
peripheral T cells, however, many of its functions in the immune system remain poorly
understood (Joshi et al., 2008; Minter et al., 2005; Palaga et al., 2003; Samon et al.,
2008; Shin et al., 2006).

1.3 Role of Notch during T cell receptor (TCR) signaling
In peripheral T cells, antigenic stimulation triggers a series of diverse
intracellular events, including the activation of protein kinases, such as p56Lck, PKCθ
and MAPKs and phosphatases, such as calcineurin (Schmitz et al., 2003). The initial
signaling is amplified through the generation of second messengers, such as DAG, IP3
and intracellular calcium ions and delivered to the nucleus, leading to regulation of
target gene expression, which is required for T cell proliferation and activation (Saito
and Yokosuka, 2006). Indeed, the unique structure between the T cell and antigen
presenting cell (APC) is required for the signal generation and signal integration for
optimal T cell responses. M. Norcross defined the term, immunological synapse (IS)
based on the structural similarity of the T cell recognition-activation process and the
cell communication processes found in other organ systems, especially the nervous
system (Norcross, 1984). Theoretically, the IS is a highly organized and dynamic
structure that shows highly-ordered distribution of molecules, first observed in the
contact area between T and B cells (Huppa and Davis, 2003).
Upon TCR stimulation along with CD28 co-stimulation, the mutual activations
of p56Lck and Zap70 initiate the phosphorylation and activation of adaptors and other
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signal components through the recruitment of molecules, sush as Lat, SLP-76, SLAP,
Grb2 (Growth factor receptor-bound protein 2), Carma1 and Dlgh that lack inherent
enzymatic activity. Hence, the proteins, such as tyrosine and serine-threonine kinases,
PI3K (phosphatidylinositol-3-OH kinase), PLCγ1 (phospholipase C-γ1) and several
small GTPases, which contain enzymatic activity, are necessary for the progressive
assembly and activation of signal-transduction modules (Gaide et al., 2002; Round et
al., 2007; Shaw and Filbert, 2009). The proximal complex, called a membrane-proximal
signalosome, transmits to activate transcription factors, including NFAT (nuclear factor
of activated T cells) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells), and ultimately leads to T cell activation (Serfling et al., 2004). The TCR
signaling complex triggers the recruitment and the formation of CBM complex, which
is composed of Carma1, Bcl10 and MALT1 (mucosa associated lymphoid tissue
lymphoma translocation gene 1) which migrates to lipid rafts, leading to activation of
NF-κB (Bi et al., 2001; van Oers and Chen, 2005). PKCθ, a Ca2+-independent PKC
isoform, is recruited into the IS through the direct interaction with Carma1. Further,
PKCθ plays an essential role in activation of IKK (IκB kinase) and NF-κB when
induced by CD3ε/CD28 co-stimulation or phorbol 12-myristate 13-acetate (PMA), a
pharmacological homolog of diacylglycerol, in mature T cells.
Notch1 has been reported to associate with p56Lck and PI3K, but not Akt/PKB in
Jurkat T cells and these complexes are present in primary T cells in the presence of IL-2
(Sade et al., 2004). In addition, Notch1 colocalized with CD4, known to be part of the
IS in activated but not in resting T cells. CD4 is thought to stabilize the initial
interaction with TCR complex and MHC class II molecules and enhance signal
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transduction by recruitment of p56Lck (Benson et al., 2005). Recently, it has been found
that over-expression of cleaved Notch1 (N1ICD) in a mouse model of T-cell acute
lymphoblastic leukemia (T-ALL) and in human T-ALL cells leads to the activation of
NF-κB through the direct interaction with the I kappa B (IκB) kinase (IKK)
signalosome and enhancing IKK activity (Vilimas et al., 2007). As well, the active form
of Notch1 (N1ICD), but not the intact membrane-bound form (N1ΔE), associates with
nuclear IKKα in CaSki cells (Song et al., 2008). However, whether Notch1 can only
form a nuclear complex with IKKα or complexes with other components in the
cytoplasm remains to be determined.

1.4 Notch in T cell development
For the last decade, the function of Notch in T cell development has been
intensively studied (Figure 1.4). Numerous studies have shown that, during
development of the immune system, Notch signaling may be involved in self-renewal of
hematopoietic stem cells (HSC). Notch is further required for the fate decision of T
cells from early haematopoietic progenitors (Pear and Radtke, 2003). Although the
differences between T cells in the thymus and B cells in the bone marrow (BM), where
they develop, respectively, is fundamentally different during hematopoiesis, they share
many common developmental features including rearrangement of their antigenreceptor genes, obligatory expression of a surrogate (invariant) co-receptor component,
and ligand-dependent positive and negative selection of their mature antigen receptor
repertoires (Pear and Radtke, 2003). Although several transcription factors, including
E2A, EBF, Pax5 and Blimp-1 are essential for B cell commitment (Johnson et al., 2005),
6

the mechanisms that regulate their expression still need to be investigated. On the
contrary, T cell commitment is thought to be controlled by Notch signaling. Using lossof-function experiments, deficiency of Notch1 prevents the development of T cells, but
not the generation of B cells (Maillard et al., 2004; Radtke et al., 2000; Wilson et al.,
2001). Conversely, constitutive activation of Notch1 inhibits B cell development and
results in extrathymic T cell development (Pui et al., 1999). In addition, Dll1- or Dll4Notch1 interactions (D1) are required for T cell development and the differentiation of
late double-negative (Kuchroo et al., 2002) T cell precursors to double-positive (DP) T
cell precursors (Schmitt and Zuniga-Pflucker, 2002). There are controversial studies to
define the role of Notch in αβ vs. γδ lineage commitment. Washburn et al. (1997)
showed that BM precursors with only one functional Notch1 allele (Notch1+/−), which
bypasses the embryonic lethality from Notch−/−, cause relatively more γδ than αβ T
cells compared to wild type (wt) precursors in chimeric mice reconstituted with a
mixture of Notch1+/+ and Notch1+/− BM-derived cells. This study indicates that Notch1
signaling promotes αβ T cell development at the expense of γδ T cell development.
However, inactivation of floxed Notch1 gene in early immature thymocytes by the
proximal Lck-promoter-driven Cre recombinase results in severe impairment of αβ T
cell development, but γδ T cell development and absolute numbers of γδ T cells is still
normal, suggesting that Notch1 signaling does not influence γδ T cell development
(Kang et al., 2001). Moreover, the role of Notch signaling in the CD4 vs. CD8 lineage
decision is also controversial. Using two different Notch1ICD transgenic lines led to
conflicting outcomes where by Notch1 signaling promoted the development of CD8+ T
cells or maturation both of CD4+ and CD8+ T cells (Deftos et al., 2000; Fowlkes and
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Robey, 2002; Robey et al., 1996). Therefore, it is possible that the redundancy of Notch
receptors may compensate for the defect of Notch1 during this lineage decision.

1.5 Notch in the development of CD4+ helper T cells and regulatory T cells
Cytokines are critical for most of the biological processes and affects both the
innate and adaptive immune response. Although CD4+ and CD8+ T cells can be
distinguished from other lymphocyte types, based on their surface receptor expression,
T cells, mainly CD4+ T cells, may be further classified based on the cytokines they
produce (Figure 1.5). Indeed, T cells are a major source of cytokines, which are
required for cell-mediated immunity and allergic type responses. Several subsets of T
cells have been identified. In CD4+ T cells, at least four subsets have been identified:
helper-type 1 (TH1), TH2 and TH17 cells and various subsets of regulatory T cells (Treg).
To date, Notch proteins have been implicated in three subsets, TH1, TH2, and de novogenerated Treg. Distinct roles of Notch in TH1 and TH2 have emerged but are still
controversial, in part due to different experimental approaches. Previously, our lab
found that CD4 T cells treated with GSI in vivo or in vitro or from Notch1 antisense
(AS) mice showed defects of IFN-γ production in TH1-polarizing conditions, but not IL4 production in TH2-polarizing conditions (Minter et al., 2005). While Notch1 directly
regulated Tbx21 (T-bet) expression at the transcriptional level, directing TH1
differentiation, ectopic expression of N1ICD in CD4+ T cells restored T-bet expression,
leading to IFN-γ production in the presence of GSI. This rescue experiment suggested
that while compensatory functions among Notch proteins may exist, N1ICD expression
is sufficient to induce IFN-γ production. However, Amsen et al. (2007) and Fang et al.
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(2007) argued against the function of Notch signaling in TH1 cells, rather that Notch
exerts its role in TH2 cells. This group used both Notch1 and 2 deficient mouse models,
which showed impaired TH2 cell differentiation but intact TH1 cell differentiation. Both
groups clearly demonstrated that loss of Notch signaling lead to impaired TH2
differentiation but did not address whether Notch signaling was dispensable for TH1
differentiation because the experimental strategy was not designed for TH1 polarization
(Amsen et al., 2007; Fang et al., 2007). Hence, it is possible Notch signaling is required
both for TH1 and TH2 cell differentiation through the direct or indirect regulation of Tbet and GATA-3. Recently, administration of Jagged1-Fc has been reported to
ameliorate experimental autoimmune encephalomyelitis (EAE) in mice, while Dll1-Fc
exacerbated disease progression (Elyaman et al., 2007). Further, treatment with Dll1-Fc
increased TH1 cells in the central nervous system (CNS), while blocking Notch
signaling with anti-Dll1 antibody decreased the frequency of TH1 cells (Elyaman et al.,
2007). Therefore, the role of Notch signaling in TH1 vs. TH2 cell differentiation is still
an unresolved question and needs to be further investigated in a system where all Notch
receptors and ligands are used.
Recently, several studies have shown that Notch is necessary for the TH1 type
response. Also Notch3 has been implicated in CD4+CD25+ regulatory T cells and
suggested as a potential therapeutic target in type 1 diabetes (T1D). Anastasi et al.
(2003) demonstrated that Notch3ICD transgenic mice have increased CD4+CD25+ T
regulatory cells, both in the thymus and in the spleen. Intriguingly, these mice prevent
streptozotocin-induced autoimmune diabetes, due to the accumulation of Treg
populations in the lymphoid organs. In the pancreas, infiltrates of regulatory T cells is
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paralleled by increased expression of IL-4 and IL-10 (Anastasi et al., 2003). Several
groups have shown that over-expression of the Notch ligands Jagged1 or Dll1 leads to
the differentiation of antigen-specific CD4+ T cells to regulatory T cells, resulting in the
generation of a population of suppressive CD4+ T cells (Hoyne et al., 2000; Vigouroux
et al., 2004; Vigouroux et al., 2003; Yvon et al., 2003). A recent study has shown that
Treg cell expansion required cell-to-cell contact and Notch3 signaling, which was
mediated selectively through Jagged2 expressed by the multipotent haematopoietic stem
cells (HSC) subset (Kared et al., 2006). Previously our lab found that Foxp3 which is a
key transcription factor in regulatory T cells, is a downstream target of Notch signaling.
Furthermore, Notch and TGFβ signaling cooperate to regulate Foxp3 expression and
maintain the population of Treg cells (Samon et al., 2008).
T helper 17 cells (TH17), a subset of T helper cells producing IL-17, has been
recently discovered and characterized. This population is developmentally distinct from
TH1 and TH2. It is thought to be a key player in host defense as well as in autoimmune
disease and plays a role in tissue injury. Whether Notch signaling is involved in the
generation of TH17 cells is still under investigation. A study using blocking antibodies
against Delta1, Jagged1, a fusion chimera, Dll1-Fc or Jagged1-Fc found that Notch
signaling has no effect on the frequency of TH17 cells or Foxp3+ cells (Elyaman et al.,
2007). However, a recent study showed that Dll4, but not Dll1 influences the
development of TH17. Furthermore, toll-like receptor 9 (TLR9)-deficiency leads to
impaired Dll4 induction on APCs. The data suggest that Notch signaling, in response to
its ligands, control the frequency and the generation of TH17 cells (Ito et al., 2009).
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1.6 Notch in the development of CD8+ cytolytic T cells
Cytolytic CD8+ T cells (CTLs) are one of several key effector cells of the
immune system. Parasites outside cells can be exposed on various chances to be
attacked for clearance. However, because some bacteria, all viruses and protozoa can
infect cells and proliferate in their cytoplasm or intracellular vacuoles (phagosome or
phagolysosome), the antigens (Ag) inside cells are not accessible to antibodies (Ab) or
direct clearance. So, specific and powerful targeting mechanisms of CTLs are effective
to eliminate Ag and their infected cells without destruction of healthy cells or tissue.
Along with CD4+ TH1 cells, NK, and natural killer T (NKT) cells, CTLs can produce
IFN-γ upon antigenic stimulation. This pro-inflammatory cytokine binds to its receptor,
acting on those cells to facilitate the eradication of intracellular bacteria, viruses, and
protozoa (Abbas et al., 1996). Moreover, CD8+ T cells may also use CTL effector
molecules, like perforin and a family of serine protease known as granzymes, to lyse
target cells or use Fas ligand (FasL) for inducing apoptosis of infected in target cells
(Russell and Ley, 2002). CD8+ T cells release their cytotoxic granules at the contact
zone with the target cells and/or induce the translocation of FasL to the immunological
synapse for ligation with Fas (CD95) following engagement with peptide-MHC
complexes on target cells (Glimcher et al., 2004; Nagata and Suda, 1995). Although
some granzymes (granzyme A) function extracellularly without perforin, intracellular
roles of granzyme B require perforin to access the cell (Voskoboinik et al., 2006).
The role of Notch signaling in the lineage decision between CD4+ single
positive (SP) vs. CD8+ SP from the CD4 and CD8 double positive (DP) stage of
thymocytes is still controversial, as previously mentioned. Although there are
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conflicting opinions regarding the function of Notch from the two approaches, it has
been concluded that Notch1 signaling plays a critical role in promoting the maturation
of DP thymocytes into both the CD4+ and CD8+ lineages. Current studies have mainly
focused on the function of Notch in helper T cell differentiation and activation of the
peripheral immune system. However, recently Okamoto et al. (2008) found that Notch1,
but not Notch2 or 3, is highly expressed in effector CD8+ T cells. As well, inhibition of
Notch signaling using γ-secretase inhibitor (GSI) reversed the effects on development of
airway hyperresponsiveness (AHR) and airway inflammation, in part due to the upregulation of IFN-γ production and thus, Dll1 is an effective inhibitor of allergeninduced AHR (Okamoto et al., 2008). Maekawa et al. (2008) showed that deficiency of
Notch2 or lower expression of Dll1 leads to impaired differentiation into cytotoxic T
cells. Thus, Notch2 complexes with phosphorylated-CREB and p300 as a
transcriptional activator complex, bound on the granzyme B promoter, regulating its
gene transcription in CD8+ T cells. Together, several studies suggest that Notch
signaling is involved in regulating cytotoxic activity of CD8+ T cells (Maekawa et al.,
2008). However, the detailed mechanisms and in vivo implications of Notch signaling
need further investigation.

1.7 Eomesodermin (EOMES) as a downstream effector of Notch signaling
In the past few years, numerous downstream targets of Notch have been
identified (Amsen et al., 2009). Our lab has found several direct targets of Notch
involved in T cell differentiation and cell cycle progression (Joshi et al., 2008; Minter et
al., 2005; Samon et al., 2008; Shin et al., 2006). The functional development of TH1
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cells is directed by transcription factors. T-bet, which is a member of the T-box family,
is responsible for IFN-γ production. T-bet is considered to be the master regulator for
TH1 cells (Szabo et al., 2000). CD4+ T cells and NK cells from T-bet deficient mice are
defective in their ability to express IFN-γ (Juedes et al., 2004; Sullivan et al., 2003;
Szabo et al., 2002). In the case of CD8+ T cells, although T-bet is essential for the
differentiation of naïve cells into effector cells following antigen-specific stimulation,
T-bet−/− mice show normal IFN-γ induction and CTL function during antigennonspecific stimulation (Sullivan et al., 2003; Szabo et al., 2002). This suggests the
possibility of a T-bet-independent-pathway for differentiation of CD8+ T cells into
effector cells. Previously, it was determined that EOMES may be necessary for effector
function during the differentiation of CD8+ T cells (Pearce et al., 2003). EOMES is also
a member of the T-box transcriptional factor family and 74% similar to T-bet at the
DNA sequence level (Pearce et al., 2003). Since the conserved DNA-binding domain of
the T-box gene was first defined in Brachyury, EOMES has been implicated in the
development of organisms from Xenopus to mammals (Herrmann et al., 1990; Ryan et
al., 1996). EOMES deficiency in mice results in embryonic death (Russ et al., 2000).
Dominant negative (Kuchroo et al., 2002) EOMES expression in mice resulted in lossof-function of CD8+ T cells and ectopic expression of EOMES was sufficient to elicit
cytolytic T cell gene expression including IFN-γ, perforin and granzyme B in CD8+ T
cells (Pearce et al., 2003). We have shown that using GSI to block Notch activity in
vitro or in vivo abolishes IFN-γ production by splenic CD4+ and CD8+ T cells (Minter et
al., 2005; Palaga et al., 2003). In addition, Notch1 directly regulates T-bet expression
(Minter et al., 2005), as well as IFN-γ production at the transcriptional level (Shin et al.,
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2006). However, whether Notch1 plays a role in directing CTL function in CD8+ T cells,
either through direct induction of EOMES, perforin or granzyme B expression, remains
to be addressed.

1.8 Hypothesis and specific aims
During the past several years, Notch1 function has been implicated in peripheral
T cells. In particular, the function of Notch1 has focused mainly on activated CD4+ T
cells, as well as several subsets of CD4+ T cells, such as TH1, TH2 or Treg. Previously,
our lab demonstrated the function of Notch1 in CD4+ T cells using approaches with γsecretase inhibitor (GSI) or Notch1 antisense (AS) mice. However, preliminary and
published data from our lab suggested we further investigate the nuclear role of Notch1
in CD8+ T cells and focus on their cytolytic activity. To the contrary, growing evidences
suggest that Notch1 could associate with cytoplasmic components upon T cell
activation. Here we hypothesized that Notch functions both in the cytoplasm and the
nucleus. In this dissertation research, I addressed the nuclear function of Notch1 as a
transcriptional activator, directing CTL function of CD8+ T cells, both through direct
induction of perforin and granzyme B expression and also by regulating EOMES (Aim
1). In addition, I investigated the role of Notch1 in the cytoplasm, as suggested from
previous work in our lab and from published data of other labs. The main question in
Aim 2 is how does Notch1 regulate NF-κB activity in the cytoplasm by recruiting the
components of TCR signaling? Furthermore, I suggest a detailed molecular mechanism,
illustrating how Notch1 regulates IKK activation. In last part of this study (Aim 3), I
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further evaluate the function of Notch1 associated with NF-κB, dependent or
independent of CSL, as a main binding partner in the nucleus.
1.8.1 Aim 1: To investigate whether Notch1 regulates cytolytic effector function in
CD8+ T cells
My first aim was to determine whether Notch1 regulates the expression of
cytolytic effector molecules, following stimulation with anti-CD3ε and anti-CD28 and
OVA-specific stimulation in developing effector CTLs. Here I show that Notch
signaling in CD8+ T cells specifically regulates perforin and granzyme B expression but
does not influence Fas-FasL interactions. The data presented in CHAPTER 2
demonstrate that in CD8+ T cells stimulation with anti-CD3ε and anti-CD28, or with
OVA258-276-expressing E.G7-OVA cells, increases the levels of perforin and granzyme
B expression. Blockage of Notch expression results in reduced expression of these
molecules, as well as reduced cytolytic effector function.
1.8.2 Aim 2: To investigate the cytoplasmic role of Notch1 in T cell activation
A non-canonical cytoplasmic function of Notch has been suggested by several
studies. Notch1 may associate with adapters and kinases necessary for phosphorylation
cascades, triggering the activation of downstream targets, suggesting Notch1 may exert
distinct roles in the cytoplasm vs. the nucleus. Although the function of Notch1 has
been thought to be as a transcriptional activator, complexed with CSL, a non-cannonical
function in the cytoplasm has been suggested in a recent paper (Perumalsamy et al.,
2009). Previously, our lab found that Notch1 mediates a molecular association with
Carma1 and Bcl10 as well as PKCθ and the IKK complex. This suggests that Notch1
plays a novel role in the cytoplasm, mediating the liberation of NF-κB through the
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activation of the IKK complex, and is independent of nuclear complex formation with
other transcription factors. In CHAPTER 3, I further investigated which functional
domains of N1ICD are required for the formation of this complex through its interaction
with Carma1. These data provide insight regarding how Notch1 deficiency influences
the il-2 gene expression through NF-κB on the il-2 promoter.
1.8.3 Aim 3: To determine how Notch signaling associates with NF-κB complexes
in the nucleus, dependent or independent of CSL
Data presented in Aim 1 show that protein complexes of Notch1, CSL and/or
NF-κB are found on the perforin and granzyme B promoters, suggesting that Notch
signaling directly regulates expression of these cytolytic effector proteins. In
CHAPTER 4, I will explore whether Notch1 is required for the formation of a highly
ordered complex including CSL and NF-κB and how sequence-paired sites are
dependent or independent of their orientation as well as how the spacing contributes to
the formation of this nuclear complex on the promoter.
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Thomas Hunt Morgan
Johns Hopkins yearbook of 1891

Figure 1.1: The origin of Notch1
In 1919, TH Morgan found the notched wing of a strain of the fruit fly Drosophila
melanogaster described in “The physical basis of heredity”. From the 1980s, the Notch1
gene, referred to as TAN-1, has been studied at the molecular and protein level of its
gene product.
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Figure 1.2: Notch proteins and Notch ligands
The structural features of Notch receptors and DSL-family ligands from fly, human and
worm are displayed. RAM, the membrane-proximal RBP-J-associate molecule domain;
ANK, the Ankyrin domain; PEST, a praline-, glutamate-, serine- and threonine-rich
domain; TM, transmembrane domain; NEC, Notch extracellular subunit; DSL,
Delta/Serrate/Lag; MNNL, the terminal Notch ligand. (Gordon et al., 2008)
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Figure 1.3: Canonical Notch signaling
There are four mammalian Notch receptor types (1-4). The DSL family of ligands binds
the Notch receptor on neighboring cells, leading to successive proteolytic cleavages of
Notch. First proteolytic cleavage occurs by the protease TNFα converting enzyme and
subsequently proceeds by a γ-secretase complex, releasing the intracellular domain of
Notch (NICD). Then, NICD translocates to the nucleus, where it clears the repressor
complex with CSL, converting to activator complex with co-activators (CoA) such as
mastermind like-1 (MAML1) and histone acetyl transferase. (Amsen et al., 2009; Ang and
Tergaonkar, 2007)
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Figure 1.4: Notch-dependent T cell development
Notch 1 signaling may play an important role in self-renewal of haematopoietic stem
cells (HSCs) and is indispensable for T cell lineage commitment during thymic
development of T lymphocytes. (Grabher et al., 2006)
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Figure 1.5: CD4+ T cell differentiation
Adaptive immune responses against pathogens are directed by at least four different
types of subsets in CD4+ T cells, known as helper-type 1 (TH1), TH2 and TH17 cells and
various subsets of regulatory T cells (Treg). These cells may orchestrate the immune
response to particular types of pathogens through their distinct cytokines, which is
referred to as a signature cytokine. Some cytokines are interconnected with each type
and influence further, the regulation of other subsets. (Steinman, 2007)
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CHAPTER 2
NOTCH FUNCTIONS AS A REGULATOR FOR CYTOLYTIC EFFECTOR
FUNCTION IN CD8+ T CELLS

2.1 Introduction
A functional CD8+ T cell response is an essential component of the adaptive
immune response to many bacterial and viral pathogens (Kaech et al., 2002). Upon
engagement with antigen, naïve CD8+ T cells rapidly expand and differentiate into
CD8+ effectors, producing cytokines such as interferon-gamma (IFN-γ) and the effector
molecules perforin and granzyme B. Cytolytic CD8+ T cells (CTLs) play a key role in
the defense against intracellular bacteria and viruses, employing at least two distinct
mechanisms to mediate direct killing of infected target cells CTLs can lyse targets by
perforin-mediated release of granzyme B, a serine protease that induces apoptosis
(Catalfamo and Henkart, 2003). CTLs also express Fas ligand (FasL) and can engage
Fas on a target cell resulting in apoptosis (Nagata and Suda, 1995).
The differentiation of a naïve CD8+ T cell into a functional CTL is driven, in
part, by the T-box transcription factor Eomesodermin (EOMES). EOMES belongs to
the family of T-box transcription factors, and shares 74% homology with T-bet (Pearce
et al., 2003). EOMES plays a critical role during vertebrate development and EOMES
deficiency in mice results in embryonic death (Russ et al., 2000). Dominant negative
(Kuchroo et al., 2002) EOMES expression in CD8+ T cells results in loss-of-function of
CD8+ T cells while ectopic expression of EOMES was shown to induce expression of
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IFN-γ, perforin and granzyme B, suggesting this transcription factor is important in
differentiation of naïve CD8+ T cells into effector CTLs (Pearce et al., 2003).
Previously, we showed that signaling through the T cell receptor (TCR) in both
CD4+ and CD8+ T cells induces the activation of Notch1 (Palaga et al., 2003). Notch
proteins are single-pass transmembrane receptors that require multiple enzymatic
cleavages to produce the full-length heterodimer displayed on the cell surface (Bray,
2006). In mice and humans, four Notch genes (Notch1-4) and at least five ligands
(Delta-like1, 3 and 4, and Jagged1 and 2) have been identified (Osborne and Minter,
2007). Upon ligand-binding, Notch undergoes final processing by γ-secretase (De
Strooper et al., 1999; Struhl and Adachi, 1998), and activation of all Notch isoforms can
be effectively prevented using pharmacological inhibitors of γ-secretase (GSI) (Kopan
and Ilagan, 2004). This final γ-secretase-induced cleavage generates the mature,
intracellular signaling peptide (NICD) which translocates to the nucleus, and potentiates
the transcriptional activity associated with Notch. In the nucleus, NICD associates with
the DNA binding protein CSL (CBF1/RBP-Jκ, mammals; Suppressor of Hairless,
Drosophila; and Lag-1, C. elegans) resulting in the Notch-mediated conversion of CSL
from a repressor into a transcriptional activator.
Earlier data from our laboratory indicated Notch regulates the expression of the
T-box protein, T-bet, in TH1 cells (Minter et al., 2005). T-bet and the closely-related
protein, EOMES, both are implicated in the development of effector CD8+ T cells
(Intlekofer et al., 2007; Intlekofer et al., 2005; Pearce et al., 2003). These observations,
as well as our earlier data demonstrating TCR signaling in CD8+ T cells induces the
activation of Notch, led us to ask whether Notch signaling plays a role in the
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development or function of effector CTLs. In this report, we describe an intrinsic role in
CD8+ T cells for γ-secretase in the regulation of EOMES, perforin and granzyme B. We
also present genetic data from Notch1 antisense (AS) mice showing a reduction in
EOMES, perforin and granzyme B. Lastly we show that re-introduction of activated
Notch into GSI-treated CD8+ T cells partially rescues EOMES expression. These data
lead us to conclude that Notch is the major target of GSI and that Notch signaling is an
important component of cytolytic effector function in CD8+ T cells.

2.2 Results
2.2.1 Notch signaling regulates the expression of perforin and granzyme B in
developing effector CTLs
To address what role Notch may have in the development of effector CTLs,
splenocytes from C57BL/6 mice were pretreated with DMSO, a vehicle control, or with
an inhibitor of γ-secretase (GSI) to block Notch activation then stimulated with
antibodies against CD3ε and CD28 for 2 days. CD8+ T cells were isolated and whole
cell lysates were immunoblotted with anti-Notch1 (Figure 2.1). In control cells, we
observed increasing expression of intracellular Notch1 (N1ICD) up to 3 days following
stimulation, however, in vitro treatment with GSI significantly abrogated Notch1
expression, consistent with previous reports (Minter et al., 2005; Palaga et al., 2003).
Additionally CD8+ T cells were analyzed for IFN-γ expression by intracellular staining
(Figure 2.2). Compared to DMSO control, we noted substantial IFN-γ reduction by in
vitro treatment with GSI. We next analyzed mRNA transcripts and protein expression
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of perforin and granzyme B, two key mediators of CTL effector function. In DMSOtreated cells, stimulation for 2 days with anti-CD3ε and anti-CD28 resulted in upregulation both of perforin and granzyme B mRNA. In contrast, in vitro treatment with
GSI markedly diminished mRNA transcripts of perforin, while granzyme B was less
affected (Figure 2.3). Using intracellular staining and flow cytometric analysis of CD8+
T cells, we assessed the level of protein expression of perforin and granzyme B up to 3
days post-stimulation. Consistent with the mRNA expression profile, protein expression
both of perforin and granzyme B increased post-stimulation, and in vitro treatment with
GSI significantly reduced expression of both proteins, compared to DMSO controls
(Figure 2.4).
To further investigate, in vivo, the effects of blocking Notch signaling, we used
cells from Notch1 AS mice that have been engineered to express reduced levels of
Notch1 in lymphocytes, as well as in other cell lineages (Palaga et al., 2003). Results
obtained using cells from these animals are more modest, nonetheless, CD8+ T cells
from Notch1 AS mice exhibit reduced expression of N1ICD, compared to littermate
controls (Figure 2.5), decreased mRNA transcripts of perforin and granzyme B (Figure
2.6), as well as reduced protein expression, as determined by intracellular staining and
flow cytometric analysis (Figure 2.7). Thus, using pharmacological and genetic means
to block Notch activation in CD8+ T cells, we show that inhibiting Notch signaling also
decreases expression of the principal mediators of CTL activity in CD8+ T cells,
perforin and granzyme B, both at the transcript and protein levels.
Previous data from our lab suggested Notch activation is associated with the
proliferation of T cells as well as the activation of NF-κB and the production of the
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effector cytokine IFN-γ (Palaga et al., 2003). CD25 and CD69 was partly reduced by
the in vitro treatment of splenic T cells with GSI suggesting that both TCR signals as
well as Notch activation are required for sustained and maximal expression of these
markers of early T cell activation. Additionally Adler et al. (2003) showed that Notch
signaling enhances CD25 expression on CD4+ T cells. To determine whether purified
CD8+ T cells display altered cell surface expression of these activation markers in the
absence or presence of GSI in vitro, CD8+ T cells were isolated from splenocytes of
age-matched C57BL/6 mice and then incubated with anti-CD3ε and anti-CD28 for 2
days. As shown in Figure 2.8, GSI treatment had little to no effect on the expression of
CD25, CD44, and CD69 (Figure 2.8).
2.2.2 Notch signaling plays an intrinsic role in CD8+ T cells to regulate the
expression of perforin and granzyme B
In the experiments shown in Figures 2.1-2.4, splenocytes containing both CD4+
and CD8+ T cells were activated with anti-CD3ε and anti-CD28, followed by analysis of
perforin and granzyme B in highly purified CD8+ T cells. It is well-established that
CD4+ T cells provide cytokines, including IFN-γ, that drive the maturation of CD8+
effector cells, and we have previously reported a role for Notch1 in mediating IFN-γ
production (Shin et al., 2006). Therefore, it is possible that reduced Notch signaling in
the CD4+ population contributed, at least partially, to the diminished expression of
perforin and granzyme B observed in Figures 2.1-2.4. To address whether Notch
signaling plays an intrinsic role in the differentiation of CD8+ T cells into CTLs,
purified CD8+ T cells (Figure 2.9) were treated in vitro with GSI or DMSO, mixed with
CD8-depleted splenocytes, and stimulated for 2 days. As controls, total splenocytes
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were treated in vitro with GSI or DMSO, then stimulated for 2 days. At the end of the
culture period, cells were stained intracellularly for perforin or granzyme B and
analyzed by flow cytometry; whole cell lysates were prepared from parallel cultures to
monitor Notch inhibition. The top panel of Figure 2.10, shows results from control
experiments where total splenocytes were stimulated for 2 days in vitro with either GSI
or DMSO. After 2 days of culture, CD8+ cells were gated and intracellular expression of
either perforin (top, left panel) or granzyme B (top, right panel) was determined. As
expected from data presented in Figures 2.1-2.4, these control experiments
demonstrated that GSI effectively blocks the appearance of both intracellular perforin
and granzyme B. To address the question whether GSI works intrinsically on CD8+ T
cells, we isolated CD8+ T cells and treated them with GSI and washed them to remove
extracellular GSI. This treated CD8+ population was then mixed with CD8-depleted
splenocytes and stimulated as described above for 2 days. As described for the control
experiment, at the end of the 2 day incubation, CD8+ cells were gated and intracellular
protein levels of perforin and granzyme B determined (Figure 2.10, bottom panel).
Again, we found that GSI effectively blocks the level of intracellular perforin and
granzyme B, suggesting Notch functions intrinsically in CD8+ T cells to regulate
effector function. As a control, to ensure GSI functioned to block Notch processing in
these experiments, CD8+ T cells from Figure 2.10 were analyzed for the presence of
N1ICD, the activated form of Notch1. As shown in Figures 2.11 and 2.12, GSI
treatment significantly blocks the appearance of N1ICD. Additionally, supernatants
were harvested from these cultures and assayed for the expression of IFN-γ. As shown
in Figure 2.13, supernatants from DMSO-treated controls expressed high levels of IFN-
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γ while supernatants from GSI-treated CD8+ T cells did not secrete appreciable levels of
this cytokine (Figure 2.14).
2.2.3 Notch binds both to perforin and granzyme B promoters
To investigate whether Notch1 directly regulates transcription of CTL effector
molecules, we examined mouse genomic DNA, approximately 1.8 kilobases (Jerry et
al., 2002) and 0.96 kb upstream of the perforin and granzyme B promoter start sites,
respectively (Figure 2.15). Within these regions, we identified multiple putative CSL
and NF-κB binding sites. To determine whether N1ICD forms a complex with CSL on
these promoters, we performed chromatin immunoprecipitation (ChIP) analysis both on
the perforin and granzyme B promoters. We observed that N1ICD binds to both
promoters and GSI treatment abrogates N1ICD binding. We also detected CSL bound
to both promoters, however, treatment with GSI showed no effect on CSL binding. The
CSL binding site overlaps with that of the transcription factor, NF-κB (Beverly and
Capobianco, 2004; Shirakata et al., 1996; Wang et al., 2001). Previously, we reported
that N1ICD also can interact with NF-κB to directly regulate IFN-γ (Shin et al., 2006).
Therefore, we asked if NF-κB was also found bound to the perforin and granzyme B
promoters. ChIP analysis demonstrates that Notch and NF-κB occupy sites both in the
perforin and the granzyme B promoter regions analyzed, and GSI-treatment abrogates
recruitment of NF-κB to these binding sites (Figure 2.16). Taken together, these data
suggest that NF-κB and CSL both are recruited to the perforin and granzyme B
promoters and, in the case of NF-κB, interaction with nuclear complexes that require
Notch1 directly regulates these CTL effector molecules.
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2.2.4 Treatment with GSI partially blocks CTL function
To determine whether GSI influences biological function in CD8+ T cells, we
injected C57BL/6 (H-2b) mice, intraperitoneally, with E.G7-OVA cells. This syngeneic
tumor cell line was constructed by transfecting the parental EL4 cell line with cDNA
expressing a MHC-class-I-restricted-peptide of chicken ovalbumin, amino acids 258276 (OVA258-276) (Moore et al., 1988). Sixteen days after immunization, splenocytes
from these animals were collected and pretreated in vitro with GSI, or the vehicle
control, DMSO, and restimulated in culture for 5 days with γ-irradiated E.G7-OVA cell
or with EL4 cells, as a mock control for stimulation. After 5 days, CD8+ T cells were
isolated and N1ICD expression was assessed by immunoblotting and flow cytometric
analysis of intracellular staining. We found that N1ICD increased in CD8+ T cells from
mice primed with OVA258-276-expressing E.G7-OVA cells, but not in those primed with
control EL4 cells, and GSI-treatment abrogated expression of N1ICD under E.G7OVA-immunized conditions (Figure 2.17). Similarly, there was no increase in perforin
and granzyme B expression in CD8+ T cells either from E.G7-OVA- or EL4-in vitrostimulated cultures from mice primed with control EL4 cells (Figure 2.18). In contrast,
CD8+ T cells from mice immunized with E.G7-OVA showed robust induction of
N1ICD, perforin and granzyme B expression when stimulated in vitro with E.G7-OVA
cells (Figure 2.17). In vitro GSI-treatment of E.G7-OVA-primed CD8+ T cells
significantly reduced perforin and granzyme B expression during stimulation with
E.G7-OVA cells (Figure 2.18). These data demonstrate GSI treatment blocks maximal
perforin and granzyme B expression and suggest that Notch signaling, induced by
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MHC-class-I-restricted-OVA-peptide in E.G7-OVA-primed CD8+ T cells may play a
role in this process.
To further address the specificity with which GSI regulates CTL effector
functions, we asked whether the Fas-FasL pathway, which also plays an important role
in CTL-induced cell death, is regulated through targets of GSI. Firstly, as control, we
checked Fas expression on both EL4 and E.G7-OVA cell lines. Because if EL4 or
E.G7-OVA cell expresses Fas, it would not be clear how much of the killing in Figure
2.20 is due to FasL-mediated killing of CD8+ T cells. As is shown in the Figure 2.19,
little to no detectable Fas is found on either the parental EL4 or the E.G7-OVA cell
lines. And FasL was detected only in CD8+ T cells from mice primed with E.G7-OVA,
but not from mice primed with EL4 cells. Additionally, FasL expression was similar
whether CD8+ T cells were pretreated in vitro without or with GSI (Figure 2.20),
suggesting GSI, likely through its role in blocking Notch signaling, controls CTL
activity of CD8+ T cells, specifically, through its direct regulation of perforin and
granzyme B transcription, but not through FasL expression. Therefore we feel that, in
the system we report in this study, Fas/FasL killing is unlikely to be a major contributor.
To test the biological impact of GSI in CD8+ CTLs, we used a Europium (Eu)
cytotoxicity assay to measure target cell death (Nair et al., 1999). Live CD8+ T cells
from E.G7-OVA-primed mice were mixed either with E.G7-OVA- or EL4-Eu-loaded
target cells and cell lysis determined by time-resolved fluorimetry (Nair et al., 1997).
CD8+ CTLs were capable of lysing E.G7-OVA cells but not the control EL4 cell line
(Figure 2.21A, compare boxes with triangles). Specific lysis of E.G7-OVA target cells
by E.G7-OVA-primed and in vitro-stimulated CD8+ T cells approached 70% (Figure
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2.20A, closed boxes) compared to approximately 25% lysis of control EL4 target cells
(Figure 2.21A, closed triangles). Consistent with reduced expression of perforin and
granzyme B in the absence of Notch signaling, treating E.G7-OVA-primed CD8+ T
cells in vitro with GSI blocked target cell lysis, as expected (Figure 2.21A, compare
open boxes with closed boxes).
To determine the effects on CTL activity of in vivo treatment with GSI,
C57BL/6 mice were fed GSI in rodent chow formulated to deliver 5 mg/kg/day, for 3
days prior to E.G7-OVA immunization and continuing until animals were sacrificed 16
days later. CTL assays were performed using Eu-primed target cells as described above.
Similar to results obtained with in vitro GSI-treatment, lysis of E.G7-OVA-specific
target cells by E.G7-OVA-primed CD8+ T cells was attenuated in cultures of cells from
in vivo GSI-administered mice compared to E.G7-OVA-primed controls (Figure 2.21B,
compare closed boxes with open boxes). Lysis of EL4 control target cells was reduced
compared to E.G7-OVA-specific target cells (Figure 2.21B, compare closed boxes with
closed triangles), and further reduced when mice were fed GSI chow (Figure 2.21B,
compare closed triangles with open triangles). Thus, GSI, delivered either in vitro or in
vivo effectively alleviates specific target-cell lysis mediated by CD8+ CTLs.
2.2.5 Notch signaling regulates EOMES expression through direct binding to the
EOMES promoter
Differentiation of CD8+ T cells is regulated, at least in part, by the T-box
transcription factor, EOMES (Glimcher et al., 2004; Pearce et al., 2003). It has been
reported that EOMES is significantly upregulated in effector CD8+ T cells and plays an
important role in CTL effector mechanisms, as well as in mediating IFN-γ production
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(Pearce et al., 2003). To investigate whether Notch1 regulates EOMES, EOMES
mRNA and protein expression were analyzed in the presence or absence of Notch
signaling. In stimulated CD8+ T cells, inhibiting Notch activation with GSI treatment
reduced EOMES mRNA transcript, and this was confirmed in stimulated CD8+ T cells
from Notch1 AS mice. Protein expression of EOMES was also reduced in stimulated
CD8+ T cells treated in vitro or in vivo with GSI, compared to controls (Figure 2.22). As
reported by others, T-bet also is expressed in activated CD8+ T cells (Intlekofer et al.,
2007; Intlekofer et al., 2005). Consistent with these reports, we observed T-bet
expression in DMSO-treated cultures. However, as with EOMES expression, we found
GSI treatment significantly reduces the expression of T-bet protein (Figure 2.22).
To verify whether Notch1 directly regulates EOMES expression, we examined
approximately 1.2 kb of genomic DNA upstream of the mouse EOMES start site and
again identified multiple putative binding sites for CSL and NF-κB (Figure 2.23). Using
ChIP analysis, we determined that Notch1 forms a complex with CSL on the EOMES
promoter (Figure 2.24). Treatment with GSI, in vitro, prevented recruitment of Notch1
to the promoter, although CSL binding remained intact, showing binding patterns
similar to those observed with the perforin and granzyme B promoters (Figure 2.16).
Additionally, NF-κB could also be found on the EOMES promoter, and pretreatment
with GSI prevented its co-recruitment to NF-κB binding sites (Figure 2.24). These data
suggest that CSL and NF-κB both are recruited to the EOMES promoter in a nuclear
complex with Notch1 to directly regulate EOMES transcription.
EOMES expression is sufficient to drive production of IFN-γ (Pearce et al.,
2003), demonstrating IFN-γ is an excellent “readout” of EOMES activity. We
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previously showed that IFN-γ production in CD8+ T cells requires Notch activation
(Palaga et al., 2003) and we present data here demonstrating that ectopic expression of
N1ICD in CD8+ T cells drives IFN-γ even in the presence of GSI (Figure 2.25). We
reasoned if Notch-induced expression of IFN-γ in CD8+ T cells is mediated through
Notch-regulation of EOMES, the expression of EOMES should also rescue IFN-γ
expression in the presence of GSI. Therefore, we asked whether ectopic expression of
EOMES is sufficient to drive IFN-γ in CD8+ T cells. Our data show that retrovirally
transduced EOMES expression drives IFN-γ in CD8+ T cells even in the presence of
GSI, indicating that EOMES functions downstream of Notch signaling to regulate IFNγ expression (Figures 2.26 and 2.27).

2.3 Discussion
During the course of an infection, two distinct pathways regulate the cytolytic
function of both NK and CD8+ T cells; namely granule exocytosis and Fas-FasL
interactions (Kagi et al., 1994; Nakazawa et al., 1997). The granule exocytosis pathway
utilizes the pore-forming molecule, perforin and the protease, granzyme B, while the
Fas-FasL pathway facilitates programmed-cell-death by aggregation of Fas (CD95) on
target cells. Notch signaling has been implicated in the development of NK cells
(Aoyama et al., 2007; De Smedt et al., 2007; DeHart et al., 2005; Lehar et al., 2005;
Rolink et al., 2006) as well as the development of CD8+ T cells in the thymus, although
the latter is still controversial (Doerfler et al., 2001; Pear and Radtke, 2003; Robey and
Fowlkes, 1994; Robey and Schlissel, 2003; Wolfer et al., 2001; Yasutomo et al., 2000).
However, the regulation of expression of perforin and granzyme B, in NK or CD8+ T
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cells has not been well-studied. Here we show that Notch signaling in CD8+ T cells
specifically regulates perforin and granzyme B expression but does not influence FasFasL interactions. The data presented in this study demonstrate that, in CD8+ T cells,
stimulation with anti-CD3ε and anti-CD28, or with OVA258-276-expressing E.G7-OVA
cells, increases the levels of perforin and granzyme B expression and blockade of Notch
expression results in reduced expression of these molecules, as well as reduced cytolytic
function. Furthermore, we show that protein complexes of Notch1, CSL and/or NF-κB
are found on the perforin and granzyme B promoters, suggesting that Notch signaling
directly regulates expression of these cytolytic proteins.
Using a pharmacological inhibitor of γ-secretase, in vitro or in vivo, we show
that loss of Notch signaling results in down-regulation of perforin and granzyme B
expression, in addition to diminished CTL activity, in GSI-treated CD8+ T cells.
Because GSI blocks activation of all four Notch proteins, the experiments described
here implicate Notch in the regulation of perforin and granzyme B, but do not determine
which unique family member(s) are critical to this process. There are also several other
potential targets of GSI in the immune system. In addition to Notch, CD43 and CD44
are thought to be cleaved by γ-secretase (Kopan and Ilagan, 2004). Therefore, the
interpretation of data obtained solely through the use of GSI can be confounding. In the
experiments reported in this study, we employed the use of Notch1 AS mice to confirm
and extend our observations using GSI treatment. Notch1 AS mice exhibit 30-40%
decreased Notch1 activity compared with control mice, however no differences were
observed for Notch2, 3 and 4 (Palaga et al., 2003). We show that both perforin and
granzyme B expression are reduced in activated CD8+ T cells from these animals,
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suggesting that the effects obtained using GSI treatment are due, at least in part, to
blockade of Notch activity. Additionally, EOMES expression in Notch1 AS mice is
reduced, again providing genetic evidence for Notch regulation of EOMES.
We suggest the role played by Notch in the development of CTLs is intrinsic to
the CD8+ T cell. Although the mechanism is not entirely defined, it is clear that CD4+ T
cells play an important role in the CD8+ T cell response (Bevan, 2004). In the
experiments described in Figures 2.1-2.4, we stimulated total splenocytes with
antibodies to CD3ε and CD28 and then used flow cytometric analysis to examine
expression of perforin and granzyme B in CD8+ T cells. Therefore both CD4+ and CD8+
T cells were exposed to these stimulation conditions. This raised the possibility that the
role of Notch signaling in perforin and granzyme B expression could be due indirectly
to help provided by CD4+ T cells. To rule out this possibility, we prepared highly
purified CD8+ T cells and pre-treated these cells with GSI for 30 minutes. These cells
were then mixed with CD8-depleted splenocytes, stimulated with anti-CD3ε and antiCD28 for 2 days, and assayed for intracellular expression of perforin and granzyme B.
We found decreased levels of both CTL effector proteins under conditions whereby
CD8+ T cells were pre-treated with GSI. These data provide strong evidence that Notch
signaling is an intrinsic requirement for perforin and granzyme B expression in
developing CTLs. Because CD8+ T cells were pre-treated for only 30 minutes and then
washed, the data also suggest that the Notch-dependent event(s) occur within the first
several hours following activation of CD8+ T cells. While it may be surprising that GSI
treatment for the first 30 minutes of activation blocks expression of perforin and
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granzyme B, we previously have shown that such a treatment protocol also blocks IFNγ production in CD4+ T cells (Minter et al., 2005).
In Figure 2.21, we provide in vitro and in vivo evidence that GSI partially blocks
the development of CTLs. The data presented in Figure 2.21A were obtained by
immunizing mice with E.G7-OVA cells and restimulating CD8+ T cells in the presence
of either GSI or control, DMSO. Cells treated with GSI displayed reduced ability to kill
E.G7-OVA targets. In Figure 2.21B, we show data from CTLs generated in vivo in
animals fed GSI in rodent chow. Animals fed GSI display significantly reduced levels
of killing as compared to animals fed standard chow. As discussed above, these
experiments implicate GSI in the development of effector CTLs and only indirectly
suggest a function for Notch in this process. However, we also provide evidence that
Notch signaling is reduced by both the in vitro and in vivo treatment with GSI. We also
show in earlier data that Notch signaling is critical in the expression of EOMES,
perforin and granzyme B (Figures 2.1-2.7). These three molecules are critical in the
development of CTLs therefore we suggest Notch may play an important role in the
development of CTLs. A recent publication from the laboratory of Yasumoto and
colleagues (Maekawa et al., 2008) demonstrating a cooperative role for Notch2 and
CREB1 signaling in T cell cytotoxicity is consistent with our data.
In 2005, Reiner and colleagues reported that effector CD8+ T cell function is
controlled, at least in part, by the T-box transcription factor, EOMES (Intlekofer et al.,
2005). These data and our own data demonstrating a role for Notch in the regulation of
a related T-box protein, T-bet, prompted us to ask whether Notch also regulates

36

EOMES expression. As shown in Figure 2.17B, Notch, CSL and NF-κB all bind the
EOMES promoter in a Notch-dependent fashion.
Previously we showed that Notch1 plays a critical role in the expression of IFNγ in CD4+ cells. The data presented in this study demonstrate a role for Notch in IFN-γ
production in CD8+ T cells as well. Because our data demonstrate direct regulation of
EOMES expression by Notch occupancy on the EOMES promoter, it is possible that
Notch regulates IFN-γ production through EOMES. However a recent report by Mayer
et al. (Mayer et al., 2008) demonstrates a critical role for T-bet in in vivo IFN-γ
production by CD8+ T cells during infection and suggests that both T-box proteins,
EOMES and T-bet, contribute to IFN-γ expression (Mayer et al., 2008). In this study,
we show that inhibition of Notch expression with GSI, blocks expression both of
EOMES and T-bet. We also present data showing reintroduction of EOMES, as a
downstream target of Notch signaling, into GSI-treated cells rescues, at least in part,
IFN-γ production. Therefore our data are consistent with the reported roles both for
EOMES and T-bet in the regulation of IFN-γ expression in CD8+ T cells and indicate
that Notch regulation of EOMES is an important factor in IFN-γ production in CD8+
effector T cells.
Here we reveal a novel role for Notch in regulating the effector functions of
CD8+ CTL cells through the modulation of targeted cell lysis and IFN-γ production.
This direct regulation by Notch of perforin, granzyme B and EOMES may contribute to
the effective clearance of pathogens. It may also provide a possible link to the
destructive pathology seen in autoimmune diseases such as type I diabetes, multiple
sclerosis and rheumatoid arthritis. Identifying this critical function of Notch signaling in
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CD8+ T cells expands our insight into autoimmune conditions and may also be useful in
the design of novel therapies for these diseases.
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Figure 2.1: Notch1 expression in CD8+ T cells from splenocytes stimulated with antiCD3ε and anti-CD28
CD8+ T cells were isolated from splenocytes that were stimulated for 2 days and whole
cell lysates were analyzed for Notch1 expression by immunoblotting. Upper bands
represent extracellular and transmembrane portions of Notch1; lower bands are N1ICD.
GAPDH; glyceraldehyde-3-phosphate dehydrogenase. (Cho et al., 2009)
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Figure 2.2: IFN-γ production in CD8+ T cells from splenocytes stimulated with antiCD3ε and anti-CD28
Isolated CD8+ T cells as in Figure 2.1 were used for analysis of IFN-γ expression by
intracellular staining and flow cytometry. Non-filled peaks indicate the isotype controls.
(Cho et al., 2009)
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Figure 2.3: Notch-dependent mRNA of perforin and granzyme B expression in CD8+ T
cells
CD8+ T cells were isolated from the stimulated splenocytes used to determine the
expression of perforin and granzyme B by Q-PCR. For these experiments, stimulations
were carried out for 1-3 days by anti-CD3ε and anti-CD28. Data shown represent one of
three independent replicates. (Cho et al., 2009)
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Figure 2.4: Notch-dependent protein expression of perforin and granzyme B in CD8+ T
cells
Parallel samples as Figure 2.3 were used to determine the expression of perforin and
granzyme B by intracellular staining followed by flow cytometric analysis. Open peaks
represent isotype controls. Data shown represent one of three independent replicates.
(Cho et al., 2009)
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Figure 2.5: Reduced levels of active Notch1 in CD8+ T cells from Notch1 AS mice
Splenocytes from Notch1 AS mice were stimulated with anti-CD3ε plus anti-CD28 for
2 days, CD8+ T cells were isolated and used for immunoblotting to analyze whole cell
lysates for N1ICD expression (upper panels). Graph represents band intensities
normalized against GAPDH. (Cho et al., 2009)
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Figure 2.6: Reduced mRNA levels of perforin and granzyme B in CD8+ T cells from
Notch1 AS mice
Semi-quantitative RT-PCR was performed to assess perforin and granzyme B mRNA
transcript expression in CD8+ T cells from Notch1 AS mice (upper panels).
Quantifications of the relative expression of perforin and granzyme B transcripts are
represented in lower panels. (Cho et al., 2009)
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Figure 2.7: Notch-dependent protein expression of perforin and granzyme B in CD8+ T
cells from Notch1 AS mice
Splenocytes from Notch1 AS mice were isolated and stimulated with anti-CD3ε plus
anti-CD28 for 2 days and intracellular staining was conducted to determine the
percentage of CD8+ T cells expressing N1ICD, perforin and granzyme B; blank peaks
indicate isotype controls. Data shown represent one of at least three independent
replicates. (Cho et al., 2009)

45

Figure 2.8: No discernable effect of in vitro GSI treatment on early activation markers
on CD8+ T cells
CD8+ T cells were isolated from splenocytes and activated for 2 days with anti-CD3ε
and anti-CD28 in the presence of GSI or DMSO control. Following activation, purified
CD8+ T cells were assayed for CD25, CD44 and CD69 expression. As shown above,
treatment with GSI was no discernable effect on early markers of T cell activation in
CD8+ T cells. Blank peaks indicate isotype controls. (Cho et al., 2009)
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Figure 2.9: The purity of the isolated CD8+ T cells
CD8+ T cells were isolated from splenocytes of C57BL/6 mice to > 96% purity (right
panel), treated them with GSI in vitro, washed them twice with 1xPBS and mixed them
with CD8-depleted antigen presenting cells (APCs) that were purified to > 99% (left
panel). (Cho et al., 2009)
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Figure 2.10: Direct regulation of perforin and granzyme B in CD8+ T cells by intrinsic
Notch signaling
Purified CD8+ T cells from unstimulated splenocytes were pretreated in vitro with GSI,
washed two times, mixed with CD8-depleted cells then stimulated with anti-CD3ε and
anti-CD28. As a control, similar to Figure 2.4, stimulated bulk splenocytes in the
absence or presence of GSI in vitro were compared (upper 4 panels). Using intracellular
staining and flow cytometry, the percentages of CD8+ T cells expressing perforin and
granzyme B after 2 days were determined. All perforin+ or granzyme B+ plots are gated
on CD8+. (Cho et al., 2009)
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Figure 2.11: N1ICD expression in CD8+ T cells treated in vitro with GSI
CD8+ T cells were isolated from splenocytes, pretreated in vitro with GSI then
stimulated with anti-CD3ε plus anti-CD28 for 2 days. The N1ICD inhibition was
verified by immunoblot (upper panel); HSP70 was used as a loading control (lower
panel). (Cho et al., 2009)
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Figure 2.12: N1ICD expression in CD8+ T cells from Notch1 AS mice or from wild
type mice treated in vivo with GSI
N1ICD expression was determined in total lysates from CD8+ T cells from Notch1 AS
mice (upper panel) either unstimulated, or stimulated with anti-CD3ε plus anti-CD28
for 2 days, or from unstimulated or stimulated splenocytes from in vivo GSI-treated
mice (lower panel). Results in each panel are representative of at least two separate
experiments. (Cho et al., 2009)
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Figure 2.13: IFN-γ expression in CD8+ T cells treated in vitro with GSI
CD8+ T cells prepared as in Figure 2.10 were sitmulated for 1-3 days, supernatants were
harvested and IFN-γ determined by ELISA. Data represent the mean +/- s.d. of three
individual replicates. (Cho et al., 2009)
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Figure 2.14: IFN-γ secretion in CD8+ T cells from Notch1 AS mice or from wild type
mice treated in vivo with GSI
ELISA was used to assess IFN-γ levels in the supernatants from similarily-prepared
cells in Figure 2.13, stimulated for 1-3 days. Results in each panel are the mean +/- s.d.
of at least two separate experiments. (Cho et al., 2009)
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Figure 2.15: Analysis of the murine perforin and granzyme B promoters for ChIP
Consensus binding sites for CSL and NF-κB upstream of the respective start sites on (A)
perforin and (B) granzyme B promoters were identified and considered for designing
primers to amplify these regions using PCR. (Cho et al., 2009)
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Figure 2.16: Direct binding of Notch1 on the perforin and granzyme B promoters
ChIP analysis was used to determine what nuclear binding partners could be identified
on the promoters of (A) perforin and (B) granzyme B. PCR primers were designed to
amplify putative binding sites for CSL and NF-κB; we performed PCR using 5 µl of
DNA eluates and equal volumes of input. Data shown represent one of at least three
independent replicates. (Cho et al., 2009)
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Figure 2.17: Different N1ICD expression in CD8+ T cells stimulated by specific OVA
peptide in the absence or presence of GSI
To study the effects of OVA-specific antigen-stimulation on N1ICD expression in the
presence of GSI, OVA-specific CD8+ T cells were prepared, as described in Methods of
CHAPTER 5. Briefly, C57BL/6 mice were immunized with phosphate buffered saline
(PBS), as a negative control, with the parental EL4 cell line as a mock control, or with
E.G7-OVA cells, engineered to express an OVA peptide. After 16 days, splenocytes
were harvested from these mice, pretreated in vitro with GSI then stimulated with the
OVA-specific E.G7 cells for 5 days. N1ICD expression was determined by (A)
immunoblotting and (B) intracellular staining. Dotted peaks represent the conjugated
isotype control. (Cho et al., 2009)
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Figure 2.18: Notch-dependent perforin and granzyme B expression following OVA
peptide stimulation of CD8+ T cells
Together with Figure 2.17, intracellular staining and flow cytometric analysis were used
to assess the percentages of CD8+ T cells expressing perforin and granzyme B. Open
peaks represent the conjugated isotype control. Data shown are representative of three
individual replicates. (Cho et al., 2009)
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Figure 2.19: Fas expression of EL4 or E.G7-OVA cells
The Fas expression of EL4 or E.G7-OVA cells was checked by cell-surface staining and
flow cytometry. Results are representative of two individual experiments.
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Figure 2.20: FasL expression of CD8+ T cells following stimulation by specific OVA
peptide
The FasL expression of OVA-specific CD8+ T cells was evaluated by flow cytometric
analysis after cell-surface staining and immunoblotting of whole cell lysates. Blank
peaks indicate isotype controls. Results are representative of three separate experiments.
(Cho et al., 2009)
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Figure 2.21: Blocking Notch signaling attenuates the CTL activity of OVA-specific
CD8+ T cells
(A) C57BL/6 mice were immunized with E.G7-OVA cells (boxes) or EL4 cells, as a
mock control (triangles). After 16 days, splenocytes were harvested from these mice,
pretreated in vitro with DMSO (closed symbols) or with GSI (open symbols), and
stimulated with OVA-specific E.G7 cells for 5 days. Live CD8+ T cells were isolated
and an antigen-specific cytotoxicity assay, using europium (Eu)-loaded target cells, was
used to determine the percent of specific lysis. (B) C57BL/6 mice were fed control
chow or chow containing GSI (LY chow) beginning 3 days prior to immunizing with
E.G7-OVA (boxes) or EL4 (triangles) cells and continuing until splenocytes were
harvested 16 days later. Splenocytes were stimulated with OVA-specific E.G7 cells for
5 days, live CD8+ T cells isolated from the splenocytes of control-fed (closed symbols)
and GSI-fed (open symbols) mice and the Eu-cytotoxicity assay was performed, as
above. For specific lysis, 5000 target cells (T = OVA-specific E.G7-OVA or EL4, as
control) were used with 25,000, 50,000 or 100,000 effector cells (E = CD8+ T cells), for
E:T ratios of 5:1, 10:1, and 20:1, respectively. The data shown in the cytotoxicity assays
represent the mean + s.d. of three independent replicates. Data shown are representative
of three independent replicates. (Cho et al., 2009)
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Figure 2.22: EOMES expression in CD8+ T cells
For in vitro treatment of CD8+ T cells (upper panels), splenocytes were harvested from
C57BL/6 mice and CD8+ T cells were purified before pretreating them in vitro with
DMSO or GSI, stimulating them for 2 days with anti-CD3ε plus anti-CD28, and
analyzing whole cell lysates by immunoblotting for EOMES and T-bet expression. For
in vivo treatment of CD8+ T cells (lower panels), control chow, or GSI formulated in
rodent chow, was fed to C57BL/6 mice for 13 days. We then harvested splenocytes,
purified CD8+ T cells and stimulated them for 2 days with anti-CD3ε plus anti-CD28
before analyzing whole cell lysates by immunoblotting for EOMES expression. (Cho et
al., 2009)
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Figure 2.23: The analysis of murine EOMES promoter for ChIP
The designed two sets of primers to amplify the mouse EOMES promoter contain
consensus CSL- and NF-κB binding motifs. Primer set1 contains 3 binding sites for
CSL and 5 binding sites for NF-κB (>75% homology scores): primer set2 contains two
putative binding sites for each. (Cho et al., 2009)
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Figure 2.24: Direct regulation of EOMES expression by Notch1 in GSI-treated CD8+ T
cells
Two sets (set1 and set2) of PCR primers were designed to include putative binding sites
for CSL and NF-κB and ChIP analysis of the EOMES promoter was performed using
purified CD8+ T cells pretreated with DMSO or with GSI prior to stimulation for 2 days
with anti-CD3ε plus anti-CD28 (upper panels). Whole cell lysates were
immunoprecipitated using anti-Notch1, anti-CSL, or anti-p50; rabbit and goat isotype
IgG were used as negative controls. For PCR, we used 5µl of DNA elutes. Results using
primer set2 suggest that binding to putative sites within the EOMES promoter is
specific. The relative intensities of the bands in the upper panel were quantified and
were represented graphically (lower panel) which represented the mean intensity + s.d.
of three independent experiments. (Cho et al., 2009)
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Figure 2.25: IFN-γ production by ectopic expression of N1ICD
CD8+ T cells were pretreated by GSI, restored N1ICD expression by retroviral
transduction, and stimulated cells with anti-CD3ε and anti-CD28 for 2 days. Then,
retreated cells with GSI were stimulated with phorbol 12-myristate 13-acetate (PMA)
and calcium ionophore (CaI) to assess the effects of (A, upper panels) ectopic N1ICD
expression on IFN-γ production by (A, lower panel) intracellular staining and by (B)
ELISA. Infection efficiency using retroviral infection was approximately ~50%.
Intracellular staining is representative (histogram) or the mean + s.d. of three separate
experiments; ELISA data represent the mean + s.d. of three independent replicates. (Cho
et al., 2009)
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Figure 2.26: IFN-γ production by ectopic expression of EOMES
Exogenous EOMES was overexpressed in purified CD8+ T cells, intracellular staining
(left panel) and ELISA (right panel) were used to measure the ability of EOMES to
induce IFN-γ in CD8+ T cells pretreated with GSI. PMA+CaI: phorbol 12-myristate 13acetate (PMA) and calcium ionophore (CaI)-treated; GSI: γ-secretase inhibitor-treated;
EOMES: CD8+ T cells retrovirally infected with pMX-EOMES-IRES-hCD8; EOMES : CD8+ T cells retrovirally transduced with empty vector of pMX-IRES-hCD8 as
control. Data represent three or four independent replicates. (Cho et al., 2009)
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Figure 2.27: Infection efficiency for retroviral EOMES gene-transduction
Efficiencies were evaluated in every rescue-experiment and results were derived from
the experiment in Figures 2.25 and 2.26. (Cho et al., 2009)
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Figure 2.28: The suggested model in this study
Notch signaling plays an intrinsic role in the differentiation of CD8+ T cells. Gray
arrows indicate the known facts and black arrows indicate new findings in this study.
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CHAPTER 3
NOTCH FUNCTION IN THE CYTOPLASM

3.1 Introduction
Previously, using experiments with PKCθ knockout mice and a specific
PKCθ pharmacological inhibitor, rottlerin, our lab found that Notch1 may be a
downstream target of PKCθ (Figure 3.1). The inhibition of PKCθ and deficiency of its
expression leads to impaired activation of NF-κB, interferon-γ (IFN-γ), interleukin-2
(IL-2) and cell proliferation (Sun et al., 2000). Furthermore, we observed similar effects
of T cell responses using Notch1 antisense (AS) mice and using a specific
pharmacological inhibitor of γ-secretase (GSI) to inhibit proteolytic cleavage of all
isoforms of Notch. However, the precise mechanism by which Notch is involved in NFκB activation through PKCθ needs further investigation. Previously, we suggested one
mechanism by which N1ICD directly interacts with NF-κB and effectively competes
with IκBα, leading to the retention of NF-κB in the nucleus (Shin et al., 2006). Recent
data from other labs have proposed that another function of Notch1, in the cytoplasm,
may be to associate with cytoplasmic components such as adapters and kinases.
Intriguingly, recent data from two groups reported that Notch colocalized with CD4, a
known component of the immune synapse and upon T cell stimulation, endogenous
Notch1 directly associates with p56Lck and CD28, as well as PI3K from both Jurkat T
cells and in vitro activated splenic T cells (Benson et al., 2005; Sade et al., 2004). More
recently, it has been found that over-expression of cleaved Notch1 (N1ICD) in a mouse
model of T-cell acute lymphoblastic leukemia (T-ALL) and in human T-ALL cells
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leads to the activation of NF-κB through the direct interaction with the I kappa B (IκB)
kinase (IKK) signalosome and enhancing IKK activity (Vilimas et al., 2007).
Additionally, the active form of Notch1 (N1ICD), but not the intact membrane-bound
form (N1ΔE), associates with nuclear IKKα in CaSki cells (Song et al., 2008). However,
whether only through a nuclear complex with IKKα or in complexes with other
components in the cytoplasm, the role of Notch1 in driving NF-κB activation is not
entirely clear. Recent studies propose a model whereby non-canonical Notch signaling,
independent of its nuclear function, directs antiapoptotic activity of membrane-tethered
N1ICD through the mTOCR2-Akt cascade, suggesting that N1ICD may integrate with
multiple pathways, leading to a distinct role based on the cellular distribution of its
expression (Perumalsamy et al., 2009).
Previous studies in our lab found that Notch1 associates with Carma1 and Bcl10,
components of the Carma1/Bcl10/MALT1 (CBM) complex within the lipid rafts, which
is part of the immunological synapse (Shin et al., submitted). In addition, Notch1
interacted with PKCθ and the IKK complex upon TCR stimulation, leading to the
activation of NF-κB and IL-2 production. Our findings suggest that Notch1 mediates
the formation of the CBM complex with PKCθ and this interaction is required for NFκB activation and IL-2 production (Figure 3.2). However, it is necessary to further
define which functional domains of N1ICD mediate its interaction with Carma1 and
how Notch1 deficiency influences the il-2 gene expression through NF-κB on the il-2
promoter. Here, we provide data to address these questions by using truncated N1ICD
mutants to which we added the nuclear export signal (NES) and as well as through
silencing N1ICD expression.
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3.2 Results
3.2.1 Generated Notch1 mutants display cytoplasmic distribution
Notch expression is thought to be tightly regulated by proteins such as Numb,
Deltex1, and several E3 ubiquitin ligases, via intramembrane Notch-receptor proteolysis
following binding with ligand(s) on neighboring cells (Lai, 2002; Matsuno et al., 1995;
McGill and McGlade, 2003). In addition, the cytoplasmic portion of Notch1 contains
two protein-protein interaction domains, the RAM domain and six ankyrin (ANK)
repeats, two nuclear localization signals (NLS), a transactivation domain (TAD), absent
from Notch3 and Notch4, which is important for activating transcription, and a PEST
sequence important for regulating Notch degradation (Osborne and Minter, 2007). Its
downstream affects are governed by interacting and modulating proteins, and may be
mediated by specific domains of Notch1. Previously, we generated fluorescent fusion
chimera constructs of Notch1 mutant, as shown in Figure 3.3. As shown in Figure 3.4,
the deletion of ankyrin repeats (N1ICDΔANK), or of PEST and OPA domains
(N1ICDΔ2358) showed the intact nuclear localizations. However, unexpectedly, the
deletion of the RAM domain of N1ICD (N1ICDΔRAM), which resulted in dicarding
the first NLS domain, led to predominant localization in the cytosol. Several studies
identified the functional domain of Notch1, mediating the direct interaction with NF-κB
in the nucleus (Shin et al., 2006; Wang et al., 2001). However the molecular
mechanisms and the role of Notch signaling are still controversial regarding the
outcome of their affects on, mediating nuclear or cytoplasmic association with other
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proteins (Bellavia et al., 2000; Benson et al., 2005; Cheng et al., 2001; Guan et al.,
1996; McGill and McGlade, 2003; Osipo et al., 2008; Perumalsamy et al., 2009; Shin et
al., 2006; Song et al., 2008; Vilimas et al., 2007; Wang et al., 2001). To address which
domains of Notch1 are required for its interaction with Carma1, we cotransfected these
mutants with wild type (wt) Carma1 into 293T cells and then subjected them to coimmunoprecipitation with an antibody specific for GFP. As shown in Figure 3.5, we
detected the strong interaction between Carma1 and N1ICD-NES, but not N1ICD.
Moreover, we also detected the direct interaction between Carma1 and all N1ICD
mutants, except N1ICDΔRAM-NES which lacks amino acids 1759-1848 of the RAM
domain. These data demonstrate that the N-terminal region of N1ICD, including the
RAM domain, is responsible for the interaction of N1ICD with Carma1.
3.2.2 Functional domains of N1ICD mediate the interaction with Carma1
Previously, we found that only cytosolic N1ICD (N1ICD-NES) binds to Carma1
in cytoplasm. It is difficult to conclude which domains of N1ICD are critical for
mediating its interaction with Carma1 in the cytoplasm, based on their different
expression pattern in the nucleus vs. in the cytoplasm, as well as their weaker
interactions, as shown in Figures 3.4 and 3.5. Therefore, we had to first induce
predominant expression patterns of each mutant N1ICD protein in the nucleus vs. the
cytoplasm. Specifically, GFP-N1ICD mutants were modified by the inclusion of an
additional NES to reduce nuclear levels, as described in Figure 3.6, and then expressed
in 293T cells (Figure 3.7). The addition of the NES sequence to GFP-N1ICD mutants
promoted its cytosolic retention (Figure 3.7), compared to N1ICD mutants without the
additional NES (Figure 3.4). Then, to address which domain of Notch1, using mutants
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constructs with NES, are required for the interaction of Carma1, we cotransfected these
mutants with wt Carma1 in 293T cells and subjected them to co-immunoprecipitation
with GFP antibodies. As shown in Figure 3.8, we detected direct interaction between
Carma1 and N1ICD mutants except the one with a deleted RAM domain N1ICD
(N1ICDΔRAM), comparable to interaction with N1ICD-NES. These data further
support the idea that the N-terminal region of N1ICD, including the RAM domain, is
responsible for the interaction of N1ICD with Carma1, and this association occurs in the
cytoplasm.
3.2.3 Notch1 deficiency influences il-2 gene expression through NF-κB on the il-2
promoter
Upon antigenic stimulation with CD28 co-stimulation to T cells, IL-2
transcription from the il-2 gene is highly inducible. While the regulatory regions of the
human il-2 promoter have been extensively studied, it has been established that -300
nucleotides (nt) upstream from the start of transcription was sufficient for maximal
activity in transient transfection assays in Jurkat T cells (Durand et al., 1987; Fujita et
al., 1986). To date, many studies have revealed the highly inducible nature of the il-2
promoter is likely to be the result of coordinate binding of many transcription factors to
their recognition sequences on the promoter (Brunvand et al., 1993; Garrity et al., 1994;
Rothenberg and Ward, 1996; Ward et al., 1998). NF-κB is one of transcription factors,
which regulates il-2 gene expression. We tested whether Notch1 is required for il-2
gene expression on the il-2 promoter through the regulation of NF-κB activity.
Previously, we found that direct interaction of Notch1 to NF-κB modulates nuclear
retention of NF-κB leading to IFN-γ production (Shin et al., 2006). We also found that
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the cytosolic function of Notch1 may regulate the activation of NF-κB through IKK,
influencing IL-2 production. To determine whether this regulation is mediated by the
promoter regulation, influencing the transcription of il-2 gene, we analyzed the
promoter of the il-2 gene (Figure 3.9) and designed three sets of primers; one primer set
has a NF-κB binding site on the proximal region (Region A) as previously described
(Lai et al., 1995); another has no NF-κB binding site for target nucleotide sequences
(Region B); the third targets the NF-κB binding site on the distal region from the
transcription start site of the il-2 promoter (Region C) (Figure 3.10). Jurkat T cells of
Notch1-deficient or mock control were stimulated with plate bound anti-CD3ε and antiCD28 antibodies for 1 hr and, then, harvested for chromatin immunoprecipitation
(ChIP) assays using anti-p50, anti-c-Rel, or anti-p65 antibodies to precipitate proteins
cross-linked to DNA. After releasing proteins, PCR was used to amplify indicated
regions of the il-2 promoter containing NF-κB binding sites (Figure 3.11). p50 and cRel are unexpectedly pre-bound only at Region A, but not Region B or C in the il-2
promoter, however the binding affinity of p50 and c-Rel was increased upon anti-CD3ε
and anti-CD28 stimulation. Several combinations of c-Rel, p65, and p50 complexes
bind the CD28 responsive element (CD28RE) in the proximal il-2 promoter (Lai et al.,
1995). In addition, p65 is thought to function as a potent transcriptional activator of the
CD28RE of the il-2 promoter and other lymphokine promoters (Lai et al., 1995).
Although p65 is highly expressed in Jurkat T cells (Kang et al., 2006; Nolz et al., 2007),
DNA binding of p65 only depends on anti-CD3ε and anti-CD28 stimulation as shown
in Figure 3.11. Expectedly, the absence of Notch1 expression in Jurkat T cells abolished
the recruitment of NF-κBs, p50, c-Rel and p65 on the il-2 promoter. These results
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demonstrate that Notch1, responsible for IKK activation is required for the functional
regulation by Rel/NF-kappa B transcription factors on the il-2 promoter, mediating IL-2
production.

3.3 Discussion
An extracellular domain of Notch1, which is a member of Type 1
transmembrane protein family, consists of multiple epidermal growth factor-like (EGF)
repeats for mediating appropriate ligand binding and an intracellular domain is
constructed with multiple domains for mediating protein-protein interaction,
transcriptional activation and proteolytic degradation. After sequencial cleavage, it has
been thought that N1ICD translocates to the nucleus to regulate transcription of target
genes. Within recent years, it has been reported that Notch colocalizes with CD4, a
component of the immune synapse, upon T cell stimulation. Endogenous Notch1 also
directly associates with p56Lck and CD28, as well as PI3K from both Jurkat T cells and
in vitro activated splenic T cells (Benson et al., 2005; Sade et al., 2004). These data
suggest a cytoplasmic function for Notch. Previously, we investigated the cytoplasmic
role of Notch1 in T cell activation and found that N1ICD physically associates with
Carma1 and Bcl10 following T cell stimulation. Here, we found that this interaction is
mediated by the N-terminal region of N1ICD including RAM domain (Figures 3.5 and
3.8). Additionally, our previous finding showed that the deficiency of Notch1 prevents
the interaction among Carma1, Bcl10 and PKCθ and attenuates IKKα activity and the
phosphorylation level of IκBα, mediating NF-κB activation. As well, the reduced
activity of IKKα abrogates the recruitment of p50, c-Rel and p65 on human il-2
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promoter, leading to IL-2 production. And, finally, it has been reported that Notch
signaling is involved in the regulation of IL-2 responsiveness, through IL-2 production
and IL-2Rα expression.
Carma1, a member of the MAGUK family of kinases, encodes a protein that
contains a caspase recruitment domain (CARD), a coiled-coil domain, a PDZ domain, a
Src homology 3 (SH3) domain, and a C-terminal guanylate kinase domain (Rebeaud et
al., 2007). Upon TCR engagement, Carma1 is recruited to the immunological synapse,
along with Bcl10 via CARD-CARD interactions (Wang et al., 2004). Previous studies
using amino acid substitution experiment in several domains of Carma1 revealed such
domains in Carma1 mediating protein-protein interactions, so called scaffold protein
(Che et al., 2004; Lee et al., 2005). As well, the fact that the SH3 domain of Carma1 is
important for lipid raft recruitment implies that this scaffold functions to recruit
signaling molecules to assemble multimolecular signaling complexes and target for the
site of immunological synapse upon TCR engagement (Wang et al., 2004). However,
previously, we found that the deficiency of Notch1 expression failed to form a CBM
complex, suggesting the function of Notch is to assemble each components of the CBM
complex. The fact that the deficiency of Notch1 did not alter the endogenous expression
of Carma1 and Bcl10 may exclude the possibility of disassembly of CBM complex
caused from the reduced expression of Carma1 and Bcl10 in the absence of Notch1. A
critical step in the formation of the CBM complex is the phosphorylation both of
Carma1 and Bcl10. Whether Notch1 influences phosphorylation of either or both
protein still needs to be investigated.
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It was reported that Carma1 is inducibly phosphorylated by PKCθ (Hara et al.,
2004; Wang et al., 2002). PKCθ is the major isoform of PKC found in peripheral T
cells and moves into the immunological synapse mediating NF-κB activation, upon
TCR stimulation. The possible function of Notch1 may be to recruit PKCθ to Carma1
and Bcl10 enhancing the phosphorylation of both proteins and stabilizing the complex
formation. In the absence of Notch1, physical association of PKCθ both with Carma1
and Bcl10 did not occur. These data support the idea that Notch1 may mediate the
formation of CBM complex with PKCθ. However, whether Notch1 function as a
scaffold is at all involved with PKCθ phosphorylation of Carma1 in immunological
synapse or whether Notch1 is a direct target of PKCθ remains to be elucidated. Recent
elegant studies using a mouse with a T cell-specific deletion of phosphoinositidedependent kinase 1 (PDK1) suggested that PDK1 is essential for integrating the TCR
and CD28 signals, mediating the recruitment of the CBM complex and the activation of
NF-κB, but not affecting the kinases p38 and Jnk or NFAT transcription factor which
are also important for T cell survival and activation (Park et al., 2009). Notch1 was
reported to associate with CD28 both from Jurkat T cells and in vitro activated splenic
T cells (Sade et al., 2004). Upon CD28 co-stimulation, Notch1, which lacks catalytic
activity, may recruit the adapters and the kinases necessary for the NF-κB
phosphorylation cascade and mediate the liberation of NF-κB through the activation of
IKK complex. However, the fact that the deficiency of PDK1 in T cells leads the
inhibition of NF-κB DNA binding activity upon the stimulation with anti-CD3ε and
anti-CD28, but not with PMA and ionomycin opens a question whether the role PDK1
is only mediated by CD28 signals, resulting in the NF-κB activity. Several studies have
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shown that the phosphorylation of IκB proteins and the NF-κB response are triggered
by TCR signals and further enhanced by CD28 signals (Civil et al., 1996; Liou et al.,
1999). The defect of PDK1 followed by CD28 signaling abolishes the entire response of
NF-κB, suggesting the involvement of other components or another pathway initiated
by TCR signals.
In view of the fact that the intracellular domain, N1ICD, released from Notch1,
localizes predominantly to the nucleus, the notion that Notch1 has cytoplasmic function
is very controversial. As well, in the absence of stimulation, not only N1ICD but
cytoplasmic N1ICD (N1ICD-NES), induced the activation of transcription using an NFκB reporter (Shin et al., 2006). However, stimulation with PMA and CaI, demonstrated
the N1ICD-NES increased NF-κB reporter activity in Jurkat T cells, suggesting a
possible cytoplasmic function for Notch1. Further, we found that Notch1 physically
interacted with Carma1, which predominantly localizes in the cytoplasm and associates
with several cytoplasmic components as reported (Che et al., 2004; Lee et al., 2005;
Wang et al., 2004). These data support the possibility the Notch1 has a cytoplasmic
function. To confirm the critical domains of Notch1 mediating direct interaction with
Carma1, we used N1IIC-NES fused to N1ICD (Jeffries and Capobianco, 2000; Shin et
al., 2006) and mutants, leading to the accumulation of these proteins in the cytoplasm
(Figures 3.3 and 3.4). It has been reported that neither mutation nor deletion of two NLS
in N1ICD completely abolished nuclear distribution (Aster et al., 1997; Jeffries and
Capobianco, 2000; Kopan et al., 1994), in that N1ICD modified by inclusion of an
additional nuclear export signal (NES) greatly increased its cytoplasmic retention
(Jeffries and Capobianco, 2000; Shin et al., 2006). It is difficult to regard the real
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interaction among them when the distribution of N1ICD mutants is possibly different in
the nucleus (Figures 3.3 and 3.4) vs. the cytoplasm (Figures 3.6 and 3.7). Regardless of
predominant nuclear distribution of N1ICDΔ2202 or N1ICDΔ2358, Carma1 binding
was diminished as compared to N1ICDΔ2202 or N1ICDΔ2358 with the additional NES.
Intriguingly, although N-terminal region of N1ICD also mediates the interaction with
CSL or NF-κB (Aster et al., 1997; Shin et al., 2006; Wang et al., 2001), N-terminal
region of N1ICD is unexpectedly responsible for the interaction with Carma1, rather
than ANK repeats or C-terminal region from N1ICDΔ2202 or N1ICDΔ2358.
Genetic ablation of each component of the CBM complex as well as PKCθ in
mice, demonstrate that macromolecular assembly among these proteins link TCR
proximal signaling events to the activation of IKK complex, leading to NF-κB
activation and IL-2 production (Egawa et al., 2003; Ruland et al., 2001; Ruland et al.,
2003; Sun et al., 2000). NF-κB activation through CBM complex formation with PKCθ
is indispensible for IL-2 production during T cell activation. For decades, numerous
studies have shown that the promoters of the il-2 gene both in human and mouse are
governed by NF-κB. Through the cytoplasmic function of Notch1, we propose that
Notch1 promotes the transcription of il-2 gene by direct regulation of NF-κB. In
previous studies, N1ICD has been suggested to control directly the transcription of
several downstream targets in a CSL-dependent manner, followed by classical Notch
signaling (Joshi et al., 2008; Minter et al., 2005; Samon et al., 2008). Previously, we
demonstrated that N1ICD directly interacts with NF-κB and effectively competes with
IκBα, leading to retention of NF-κB in the nucleus. In addition, intracellular Notch1
may promote the expression of IFN-γ in a CSL-independent manner through interaction
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of NF-κB. Indeed, whether the association of CSL in a complex between NF-κB and
N1ICD is required for the regulation of downstream target genes is still elusive. Of note,
the promoter region of downstream targets, we previously tested, includes both NF-κB
and CSL consensus binding motifs. As well, recent studies have shown that head-tohead CSL binding sites, called SPS (sequence paired sites), may favor cooperation with
hetero- or homo-dimeric nuclear complexes containing NICD, CSL and the coactivator
mastermind like-1 (MAML1), as compared to single sites for CSL, suggesting that
NICD complex may recruit additional DNA binding factors, leading to cooperation with
NICD/CSL complexes to activate transcription (Nam et al., 2007). We analyzed human
and mouse il-2 promoter to identify putative NF-κB and CSL binding motifs through
comparisions

of

two

web-based

(www.cbrc.jp/research/db/TFSEARCH.html,

TF

search

tools

www.genomatix.de/cgi-

bin/matinspector_prof). We found putative NF-κB binding sites both in the human il-2
promoter and in the mouse il-2 promoter, consistent with previous reports. However,
putative binding motifs of CSL were identified only in the mouse il-2 promoter, but not
in human. Presumably, between mouse and human of il-2 gene, distinct regulatory
mechanisms may govern il-2 gene transcription at the promoter level. This
interpretation of different regulation of il-2 promoter between human and mouse should
be tested by an experimental approach. Although nuclear N1ICD is likely to control IL2 production dependent of either NF-κB or CSL, a cytoplasmic function of N1ICD may
mediate to direct the transcription of il-2 through NF-κB. Our finding where
cytoplasmic N1ICD preferentially binds to Carma1 and Bcl10, mediating assembly of
proteins required for IKK activation, strongly support a cytoplasmic function of Notch1.
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Figure 3.1: The suggested model from previous studies
In peripheral T cells, antigenic stimulation which is required for T cell activation and
proliferation initiates a series of diverse intracellular events, resulting in gene
expression. Previous studies in our lab demonstrated that Notch1 is involved in T cell
activation and proliferation using various approaches. Specifically, Notch1 appears to
play a critical role in NF-κB activation through PKCθ, leading to increased IFN-γ
production. Together with data from our lab and other reports, although Notch1
functions as a transcriptional activator mainly in the nucleus, Notch1 is likely to be
involved in NF-κB activation in a direct or indirect way through an alternative pathway.
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Figure 3.2: The suggested model in this study
The cytoplasmic function of Notch is suggested to be integrated with TCR signals. The
TCR signaling complex triggers a series of tyrosine phosphorylations, required for
PCKθ activation, then leading to formation of CBM complex and recruitment of this
complex at the site of contact region between T cell and APC. Notch1 was suggested to
be involved in this process, leading to IKK activation and IL-2 production. P:
phosphorylation and Ubs: ubiquitination.
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Figure 3.3: The schematic map of Notch1 and mutant chimeras fused to GFP
Intracellular domain of Notch1 (Notch1ICD) contains recombination signal-binding
protein for CSL-associated molecule (RAM), ankyrin (ANK), two nuclear localization
sequences (NLS) and a degradation motif (PEST). The generated fluorescent fusion
chimeras of Notch1 mutant constructs were used to visualize the cellular distribution of
these proteins, and further used for co-immunoprecipitation experiments.
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Figure 3.4: The differential expression of N1ICD mutants
The indicated plasmids of N1ICD mutant chimeras were transiently transfected, then
incubated for 24 hr and examined using confocal microscopy in the green channel (488
nm, upper panels) and overlay (DIC, lower panels). Yellow scale bar represents 10 μm.
GFP-N1ICD and GFP-N1ICD-mutants show typical expression patterns in the nucleus
but only GFP-N1ICDΔRAM is located in the cytoplasm, resulting from the deletion of
first NLS.
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Figure 3.5: The identification of critical domains of Notch interaction with Carma1
Indicated expression plasmids were transiently transfected into 293T cells. Transfected
cells were incubated for 2 days and harvested for co-immunoprecipitation with antiGFP antibodies. Eluates and 1/100 of input shown was immunoblotted with anti-VSV
or anti-GFP antibodies. IP: immunoprecipitation and IB: immunoblotting.
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Figure 3.6: The addition of NES schematic map of Notch1 and mutant chimeras fused
to GFP
Intracellular domain of Notch1 (N1ICD) contains recombination signal-binding protein
for CSL-associated molecule (RAM), ankyrin (ANK), two nuclear localization
sequences (NLS) and a degradation motif (PEST). The generated fluorescent fusion
chimeras of Notch1 mutant constructs were visualized for the cellular distribution of
these proteins, and further used for co-immunoprecipitation experiments.
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Figure 3.7: GFP expressions of N1ICD or N1ICD-NES mutants
293T cells were transfected with GFP-N1ICD-NES mutant expression plasmids
described in Figure 3.6. GFP of NES-labeled constructs were expressed in the
cytoplasm, then compared with the expression in the nucleus. The subcellular
localization of Notch1 was examined using fluorescence microscopy (Nikon Diaphot
TMD).
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Figure 3.8: The interaction of RAM domain of Notch1 with Carma1
VSV tagged Carma1 plasmid (VSV-Carma1) was transiently cotransfected with EGFP
empty vector as a control (Empty), or EGFP N1ICD mutant plasmids, as indicated, in
293T cells. After 2 days, transfected cells were harvested and coimmunoprecipitated
with GFP-specific. Eluates from Co-IP were immunoblotted by anti-VSV or anti-GFP.
Ig Heavy Chain indicates immunoglobulin heavy chain. Non: transfected with VSVCarma1 only; IP: immunoprecipitation; IB: immunoblotting.
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Figure 3.9: The annotation of transcription factors in human il-2 promoter
Human il-2 promoter (NT_016354) was analyzed to identify transcription factor
binding consensus motifs using computer search (http://genomatix.de/cgi-bin/matinspector/matinspector.pl). CCAAT; CCAAT binding factors, NF-κB; Nuclear factor
kappa B, OCT1; Octamer binding protein 1, MEF2; myocyte-specific enhancer binding
factor, STAT5; Signal transducer and activator of transcription 5, E2F; E2F-myc
activator/cell cycle regulator, NF1; Nuclear factor 1, Bcl6; POZ domain zinc finger
expressed in B-Cells, SMAD; Vertebrate SMAD family of transcription factors, YY1;
Activator/repressor binding to transcription initiation site, NFAT; Nuclear factor of
activated T-cells, AP1; Activating protein 1, CREB; cAMP-responsive element binding
proteins, TATA; Vertebrate TATA binding protein factor.
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Figure 3.10: Schematic of the human il-2 promoter
The il-2 gene from the transcription start site (+1) to the distal promoter (-2000) is
shown and multiple putative binding sites identified for NF-κB. These sets of primers
were designed in Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primerblast/index.cgi?LINK_LOC=BlastHomeAd). Target regions with Region A and C
primer sets contain binding sites for NF-κB; Region B primers used as negative control.
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Figure 3.11: il-2 gene expression by the direct binding of Notch1 and NF-κB on the il-2
promoter
Notch1-deficient Jurkat T cells (siNotch1) were used for ChIP analysis compared with
mock-infected control cells, after stimulation with plate bound anti-CD3ε plus CD28 for
1 hr. ChIP assay was performing using goat anti-p50, rabbit anti-c-Rel, rabbit anti-p65,
and goat isotype and rabbit isotype control immunoglobulins, as negative controls and
visualized by PCR using 10 µl DNA eluates and 1/5 volume of input. Data shown are
representative of at least three independent experiments. Relative intensities of the
bands were estimated by ImageJ software V 1.31.
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CHAPTER 4
NOTCH FUNCTION AS A MODULATOR FOR REGULATION OF
DOWNSTREAM TARGET GENES

4.1 Introduction
Previously, we demonstrated that N1ICD directly interacts with NF-κB and
effectively competes with IκBα, leading to retention of NF-κB in the nucleus (Shin et
al., 2006). As well, we have found that N1ICD can directly regulate IFN-γ expression
through complexes formed with NF-κB on the IFN-γ promoter (Shin et al., 2006). In
this chapter, to further investigate whether the cooperation between N1ICD and NF-κB
controls the transcription of downstream targets, we initiated a series of experiments
designed to more clearly define the relationship between Notch and NF-κB in the
nucleus. Our published ChIP data (Cho et al., 2009), as shown in CHAPTER 2, reveal
that Notch is found in a nuclear complex on several promoters, including IFN-γ (Shin
et al., 2006), EOMES, perforin and granzyme B, which are important for cytolytic
effector functions in CD8+ T cells. In addition, p50 and CSL were also found in the
same region of these promoters, suggesting that Notch1 may form a nuclear complex
both with CSL- and p50-containing DNA binding domains. Thus, several genes
identified as downstream targets both of CSL and NF-κB include the regions of the
promoter, which can be potentially regulated by both CSL and NF-κB through an
overlapping DNA consensus sequence (Lee et al., 2000; Palmieri et al., 1999).
Although DNA binding consensus motifs for NF-κB are broadly identified, in fact,
some of core binding motifs of NF-κB are similar to or share the CSL binding motif.
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This is supported by data demonstrating that CSL competes with NF-κB for binding to
one of three DNase I footprinting sites, FPIII identified in the rnCGM3 promoter, so
that transactivation of the FPIII-driven promoter by NF-κB is suppressed by CSL
(Wang et al., 2001). Therefore, NF-κB may compete with CSL to occupy only one
shared binding motif in the target region of a specific promoter (Figure 4.1, Model 3).
In the presence of N1ICD, an activating complex with CSL and N1ICD may positively
affect gene transcription. The fact that Wang et al. (2001) showed binding competition
between CSL and NF-κB on a targeted promoter and the suppression of transcription
through CSL still needs to be further defined when N1ICD is expressed. It is possible
that N1ICD forms a complex together with NF-κB and CSL, allowing binding at this
trimolecular complex to a single DNA binding element on the promoter. However, it is
difficult to make a complex, void of electrostatic hindrance, that binds the same DNA
element. A general model of a transcriptional complex combined with two
transcription factors bound on the distal and proximal regions of a promoter, suggest
that CSL/N1ICD may form a complex with NF-κB/N1ICD as proposed in Figure 4.1,
Model 1. However, a recent elegant study has shown that the head-to-head CSL
binding sites, called SPS (sequence paired sites), may favor cooperation with hetero- or
homodimeric nuclear complexes containing NICD, CSL and the co-activator
mastermind like-1 (MAML1), as compared to single sites for CSL (Nam et al., 2007).
Nam et al. (2007) proposed that the NICD complex may recruit additional DNA
binding factors, leading to cooperation with NICD/CSL complexes to activate
transcription (Nam et al., 2007). Together with our data shown in CHAPTER 2, we
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propose that N1ICD/CSL cooperates with NF-κB complexes to transactivate the
transcription of a variety of genes in the immune system (Figure 4.1, Model 2).
Another issue that has emerged suggests that two adjacent binding regions are
required to increase the strength and duration of gene transcription (Ong et al., 2006).
To determine how Notch signaling associates with NF-κB complexes in the nucleus, in
a CSL-dependent or -independent manner, it is necessary to investigate the
directionality and spacing between the NF-κB binding sites and CSL binding sites on
the promoters of Notch target genes. Parallel assays of well-known Notch-responsive
promoters in several cell lines revealed that relative activation strength is dependent on
protein module and promoter context rather than the cellular context (Cave et al., 2005;
Ong et al., 2006). All four mammalian Notch proteins interact with CSL and may
recognize the orientation and distribution of the binding sites on the promoter
differently; Notch1 prefers to bind on paired sites, and Notch3 binds on single sites in
conjunction with a proximal zinc finger transcription factor (Ong et al., 2006). In
addition, it has been suggested that NICD/CSL may recruit additional DNA binding
factors that can cooperate with NICD/CSL complexes to activate transcription (Nam et
al., 2007). Based on the possibility that NF-κB consensus binding sites contains a CSL
consensus site, we investigated whether NF-κB, associated with the nuclear N1ICD
complex, may bind to one of the CSL binding sites on the promoter of Notch target
genes.

4.2 Results
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4.2.1 The EOMES promoter has the directionality and the spacing between the
NF-κB binding site and the CSL binding site, to make it a candidate for Notchdependent transcription
Although the apparent consensus sequence of DNA binding sites for NF-κB is
very broad, the core binding sites in any gene are evolutionarily conserved (Figure 4.2)
(Leung et al., 2004). We propose a model whereby Notch and NF-κB bind adjacent
regions of a promoter with the proper spacing and directionality to form stable and
effective complexes, thus influencing the transcription of target genes (Figure 4.3). To
test our proposed model, we analyzed the promoter region of the murine EOMES gene,
which is one of the Notch downstream target genes that we identified in CHAPTER 2.
Using the web-based transcription factor search tools, we identified several putative
NF-κB and CSL binding motifs on the EOMES promoter (Figure 4.4) through
comparisons

of

two

web-based

(www.cbrc.jp/research/db/TFSEARCH.html,

TF
and

search

tools

www.genomatix.de/cgi-

bin/matinspector_prof). Although several SPS sites for NF-κB and N1ICD/CSL were
identified, as suggested in Ong et al. (2006), some SPS could be excluded based on
their spacing, to avoid the conformational hindrance of two adjacent complexes on the
promoter as suggested in previous reports (Nam et al., 2007; Ong et al., 2006). Typical
SPS sites on the Hes1 promoter have been already tested by Nam et al. as two CSL
binding sites with the head-to-head orientations separated by 16 or 17 nucleotides (nt)
(Figure 4.5). Although we did not find the matched region for many SPS for two
N1ICD/CSLs on the EOMES promoter containing NF-κB and CSL binding sites, we
found that one SPS for NF-κB and N1ICD/CSL that meets the criteria required for the
head-to-head orientation containing 16 to 17 nt spacing as shown in Figure 4.4. From
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our ChIP analysis (Figure 2.26B), this region may be controlled by two complexes, NFκB/N1ICD and CSL/N1ICD, as proposed in a previous report (Nam et al., 2007).
To show the conserved sequences for NF-κB or CSL binding motif, we used a
sequence logo generator (http://weblogo.berkeley.edu/logo.cgi). A sequence logo is a
graphical representation of the conserved sequence of nucleotides and shows the overall
height of the stack for each position in the sequence, indicating the relative frequency of
each nucleic acid at that position (Schneider and Stephens, 1990). It has been suggested
that CSL competes with NF-κB for binding on the mCGM3 promoter, in that the core
binding motif of NF-κB is at least similar to or shares the CSL binding motif (Lee et al.,
2000; Palmieri et al., 1999; Wang et al., 2001). The conserved sequence in the binding
motif of NF-κB looks similar to or shares that of the CSL binding motif based on the
sequence logo, as shown in Figures 4.6 and 4.7. Thus, the oligomer from the Ig kappa B
enhancer region containing a typical NF-κB binding motif widely used for EMSA
experiments contains a nested CSL binding motif (Figure 4.8), suggesting the possible
competition between NF-κB and CSL to occupy this DNA binding motif or the
formation of nuclear complexes between NF-κB and CSL/N1ICD complex to share one
DNA binding motif. However, the identified sequences for NF-κB and CSL in the
regulatory region of the EOMES promoter are not the same as predicted and, rather,
show highly homologous regions for binding of NF-κB or CSL, indicating the
specificity of each promoter. Therefore, this region of the EOMES promoter may be
required for the DNA binding both of NF-κB and CSL, together with N1ICD, for
modulation of gene transcription.
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4.2.2 Notch1 and NF-κB distinctively regulate the transcription of genes of
immunological interest
We generated EOMES luciferase reporter constructs with fragments containing
N1ICD binding region from ChIP analysis. The PCR fragments from ChIP experiment
were inserted into pGL3-promoter plasmid (Figure 4.9) and the inserts confirmed by
sequencing. Either a Hes1 reporter construct, containing functionally important SPS
elements (Figure 4.5) (Jarriault et al., 1995), or the EOMES reporter construct was
transiently transfected with NF-κB or N1ICD expression constructs into 293T cells.
Luciferase assays were performed and analyzed 2 days post-transfection by the dual
luciferase kit (Promega) following manufacturer’s protocols. EOMES reporter activity
was increased both by N1ICD and NF-κB, suggesting that N1ICD and NF-κB, in the
presence of CSL, in 293T cells positively regulates its promoter activity, as well as NFκB alone does. However, the Hes1 promoter was only upregulated by N1ICD, but not
by NF-κB. In contrast, NF-κB increases NF-κB reporter activity, and N1ICD slightly
increases this activity. Together with data presented in Figure 4.10, we suggest the
EOMES promoter may be controlled both by N1ICD and NF-κB.
4.2.3 NF-κB and N1ICD are both required for EOMES expression
Previously, we suggested a model in which Notch1 prolongs the NF-κB activity
in T cells promoting the nuclear retention of NF-κB, p50 and c-Rel, through direct
protein interaction with N1ICD (Shin et al., 2006). It has been shown by others that
Notch1 plays an important role in the nucleus as a transcriptional activator, formed with
another transcription factor containing DNA binding motifis, in a CSL independentmanner, suggesting that CSL is not required for the regulation of Notch1 signaling in
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some cases (Amsen et al., 2004; Tu et al., 2005). As shown in Figure 4.10, both N1ICD
and NF-κB enhance the EOMES reporter activity, but not the Hes1 promoter reporter,
which has been described as a typical promoter containing two CSL/N1ICD binding
motifs with the head-to-head order with 17 nt spacing. Therefore, we determined
whether NF-κB regulates the EOMES promoter, in cooperation with Notch1 signaling.
To test this, we cotransfected the EOMES promoter reporter construct into 293T cells
together with NF-κB and N1ICD expression plasmids. Although co-transfection of NFκB with N1ICD greatly increased the EOMES reporter activity, with a constant amount
of NF-κB, increasing amounts of N1ICD slightly increased EOMES reporter activity
(Figure 4.11). Conversely, we cotransfected 293T cells with a constant amount of
N1ICD together with increasing amounts of p50 or c-Rel expression plasmids. As
shown in Figure 4.12, co-transfection of p50 with a constant amount of N1ICD
increased the reporter activity in a dose-dependent manner, as did c-Rel. Although
increasing amounts of N1ICD did not further increase the EOMES reporter activity
when transfected together with p50 and c-Rel (Figure 4.11), the EOMES reporter
activity was greatly enhanced by the increasing concentration of p50 or c-Rel
expression constructs together with a constant amount of N1ICD, indicating that NF-κB
is the limiting factor in N1ICD-mediated regulation. These data differ from previous
published data in our lab, demonstrating Notch1 is a limiting factor modulating cyclin
D3 reporter activity when co-expressed with p50 (Joshi et al., 2008). Together, the
current data and previous published data in our lab suggest the unique architecture of
individual promoters might dictate differential regulation by N1ICD, NF-κB and CSL.
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4.2.4 Notch associates with the NF-κB complex in the nucleus, in a CSL-dependent
manner
Based on the different architecture between the EOMES promoter and the Hes1
promoter as proposed in this study (Figures 4.3 and 4.4) and previously suggested in
other studies (Figure 4.5) (Nam et al., 2007; Ong et al., 2006), we further investigated
whether N1ICD and NF-κB are required for the regulation of EOMES and Hes1
promoters, in a CSL-dependent or -independent manner. We used the fibroblastic cell
line carrying the homozygous (-/-) mutation of CSL (Kato et al., 1997). We transiently
transfected EOMES luciferase reporter constructs along with NF-κB and/or N1ICD
expression constructs into CSL-deficient OT11 cells and OT13 cells, as a control line
which expresses CSL. Luciferase assay was performed and analyzed 2 days posttransfection by following the protocols described in CHAPTER 6. The data from these
experiments will indicate whether CSL is required for transcriptional activation of
EOMES and whether the N1ICD/CSL complex cooperates with the N1ICD/NF-κB
complex to regulate transcriptional activity at a promoter containing an SPS. Although
co-transfection of N1ICD and/or NF-κB could not increase the EOMES reporter
activiy in the OT11 cell line lacking CSL, N1ICD together with NF-κB further
increased reporter activity in control cell lines, OT13, as shown in Figure 4.13. These
data suggest that CSL is required for EOMES promoter regulation by Notch1 signaling,
as well as that by NF-κB. To further investigate the role of CSL in regulating the Hes1
promoter, described as a canonical downstream target of Notch signaling, we
transiently transfected the Hes1 promoter reporter constructs along with NF-κB and/or
N1ICD expression constructs into OT11 cells and OT13 cells. Consistent with
published data (Kato et al., 1997) and our data shown in Figure 4.10, N1ICD increased
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Hes1 reporter activity only in the presence of CSL (Figures 4.10, bottom panel and
4.14, black bars), but not in the absence of CSL. However, NF-κB also increased Hes1
reporter activity, when cotransfected with N1ICD in the absence of CSL (Figure 4.14,
white bars), suggesting that NF-κB may bind to the CSL binding motif in the Hes1
promoter, in the case of CSL-deficiency.

4.3 Discussion
First, I addressed the question of whether N1ICD and NF-κB promote a
synergistic signaling effect at the transcriptional level of Notch target genes in 293T
cells, then asked whether N1ICD can bind to a promoter together with NF-κB, in the
absence of CSL. The data from these experiments suggest that CSL is required for
transcriptional activation of EOMES and Hes1 genes. Thus, it is likely N1ICD plays a
cooperative role with the NF-κB complex to regulate transcriptional activity on the
EOMES promoter containing SPS. We have already observed the nuclear complex
formed with Notch and p50 on the promoters of several genes: EOMES, perforin and
granzyme B, as described in CHAPTER 2. Here, we found that the EOMES promoter
region containing NF-κB and CSL binding motif in the head-to-head orientation with 17
nt spacing is governed by both NF-κB and N1ICD. Thus, both NF-κB and N1ICD, in
cooperation with CSL, regulate the transcriptional activation of EOMES gene. Some
core binding motifs of NF-κB are similar to the CSL binding motif, suggesting CSL
may compete with NF-κB for binding on the promoter (Wang et al., 2001) (Figure 4.1,
Model 3). Therefore, in the absence of CSL, NF-κB may bind to CSL-binding motifs on
Hes1 promoter, however this binding does not occur in the presence of CSL. However,
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in OT11 cells, NF-κB and N1ICD are likely to bind the Hes1 promoter as shown in
Figure 4.14, suggesting that the N1ICD/NF-κB complex may possibly regulate the
transcription of Hes1, independent of CSL. In this chapter, I used the cell line models
which are CSL-deficient embryonic fibroblast, OT11 vs. OT13 cells as control, or 293T
cells. To further clearly-define the mechanism connecting Notch1 signaling and NF-κB
signaling, dependent on TCR and CD28 co-stimulation, using additional cell lines
generally used in other studies, such as mouse lymphoma line, EL4 or human T cell
lymphoma line, Jurkat T cells can be used to test this model. The deficiency of CSL in
these cell lines could be generated by siRNA oligos of CSL and subjected to the same
approach described in this chapter.
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Figure 4.1: Proposed regulatory models of transcription complexes
The cartoons consist of a single NICD, CSL and NF-κB, to simplify comparisons.
Models 1 and 2 show cooperation of three molecules and Model 3 indicates competition
within NICD/CSL complex and NICD/NF-κB.
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Figure 4.2: NF-κB consensus binding motif
NF-κB binding sites in promoters identified as downstream targets of NF-κB are shown.
BAFF: B cell activating factor; IL-2, -9 and -13: Interleukin-2, -9 and -13; LTα:
Lymphotoxin alpha; IκBα: Inhibitory κB alpha; CD44: T cell activation marker; CCR7:
chemokine receptor 7; GLUT5: glucose transporter protein 5; TPMT: Thiopurine
methyltransferase.
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Figure 4.3: The proposed model
Consensus binding sequences of CSL and NF-κB can be aligned same direction (1) or
opposite direction (2) on target gene promoters of Notch signaling. Both spacing and
directionality among binding motifs may be critical for molecular cooperation.
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Figure 4.4: Analysis of EOMES promoter
Spacing and directionality within NF-κB and CSL binding motifs on EOMES promoter
were determined through the comparison of two web-based TF search tools. In this
anaylsis, most NF-κB binding sequences were not similar to CSL binding sequences.
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Figure 4.5: Two typical CSL binding sites oriented head-to-head
N1ICD-CSL dimers bind on Hes1 promoter by critical spacing and directionality.
(Gordon et al., 2008; Nam et al., 2007)
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Figure 4.6: The logo of NF-κB binding concensus motif
General NF-κB consensus binding motifs were expressed with the sequence logo based
on their bit-frequency. The height indicates the relative frequency of each nucleotide at
each position.
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Figure 4.7: The logo of CSL binding concensus motif
General CSL consensus binding motifs were expressed with the sequence logo based on
their bit-frequency. The highest sequences which indicate the conserved sequences in
the binding motif look similar to the conserved sequence of NF-κB in Figure 4.5.
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Figure 4.8: The shared binding motif for NF-κB and CSL
The typical NF-κB oligomer for EMSA experiment shows the consensus binding motif
for NF-κB and CSL. Although the apparent consensus sequence of DNA binding sites
for NF-κB is very broad, core binding motifs are evolutionarily conserved. Some of NFκB motifs on promoters share the binding motif with CSL. The oligomer sequence
shown above is widely used for EMSA.
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Figure 4.9: EOMES reporter construct
Like ChIP assay, input sample was performed PCR by EOMES Set1 primers. After
PCR, specific band (472 bp) was eluted through agarose gel and cloned into pGL3
promoter vector (Promega Co.) to be used in reporter gene assays.
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Figure 4.10: The promoter activities regulated by N1ICD or NF-κB
293T cells were transiently transfected with either N1ICD or NF-κB (p50 and c-Rel)
expression constructs and the dual luciferase assay was performed after 2 days. EOMES
and Hes1 promoter reporters were introduced to examine the effects of SPS architecture
on gene regulation. Values represent the mean of three luciferase assays +/- s.d. and are
representative of three separate experiments.
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Figure 4.11: N1ICD-dependent EOMES promoter activities
EOMES luciferase reporter plasmid and pRL-CMV plasmid, as internal control, were
transiently transfected into 293T cells. N1ICD and NF-κB (p50 and c-Rel) expression
plasmids were contransfected in the indicated ratios with the reporter plasmids. N1ICD
was transfected in increasing amounts while the amount of NF-κB expression plasmid
was kept constant. Transfected cells were harvested 2 days later for dual luciferase
assay as described in CHAPTER 6. Results shown are representative of three separate
experiments. Data indicate the mean +/- s.d. of relative luciferase activity.
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Figure 4.12: NF-κB-dependent EOMES promoter activities
As a reciprocal experiment to that shown in Figure 4.9, N1ICD and NF-κB (p50 and cRel) expression plasmids were contransfected in the indicated ratios with the reporter
plasmids. The amounts of p50 and c-Rel were increased while the amount of N1ICD
expression plasmid was kept constant. After 2 days, transfected 293T cells were
harvested and the dual luciferase assay was performed as described. The values shown
are the men +/- s.d. from three independent experiments.
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Figure 4.13: CSL-dependent EOMES promoter activities
EOMES promoter reporter construct was transiently transfected with N1ICD and/or
NF-κB (p50 and c-Rel), as indicated, into OT11 (CSL-/-, white bars) or OT13 (CSL+/+,
black bars) cells. For N1ICD+NF-κB, the expression plasmids were transfected in a 1:1
ratio. Each transfected cell line was harvested 2 days later for dual luciferase assay. The
values shown for both cell lines are representative of three separate experiments, and
indicate the mean +/- s.d. of relative luciferase activity.
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Figure 4.14: CSL-dependent Hes1 promoter activities
Hes1 promoter reporter construct was transiently transfected with N1ICD and/or NF-κB
(p50 and c-Rel), as indicated, into OT11 (CSL-/-, white bars) or OT13 (CSL+/+, black
bars) cells. For N1ICD+NF-κB, the expression plasmids were transfected in 1:1 ratio.
After 2 days, the dual luciferase assay was performed on the harvested cells. Results for
both cell lines are representated as the mena +/- s.d. of three separate experiments.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
The molecular mechanisms of how the Notch pathway transmits its signals to
the nucleus and how the active complexes containing NICD are formed in the nucleus
are unknown. However, it is clear that several proteins may physically associate with
Notch from outside to inside the nucleus and competitive protein binding may regulate
the strength and the duration of Notch signaling. Although the information accumulated
over the past two decades, provides a mechanism as to how the extracellular signal by
ligand on the neighboring cells transmits to the nucleus through the Notch receptor, the
macromolecular structure of the interaction within components and the structural
changes with these interaction remains to be investigated.
In this study, the functions of Notch in the cytoplasm and the nucleus were
investigated to better define their molecular mechanisms and to further investigate the
cellular effects in CD8+ T cells (CTL), through the modulation of target cell lysis and
cytokine production. Through the direct regulation by Notch of peforin, granzyme B and
EOMES, Notch1 signaling may contribute to the effective clearance of pathogens. The
main aspect of Notch1 signaling that controls its target-gene expression is thought to
occur only in the nucleus. So, we first examined the nuclear function of Notch1 to
define its role and targets. However, from previous data in our lab, a cytoplasmic role of
Notch1 was suggested and further studied here to clearly demonstrate the molecular
complex formation with several cytoplasmic components and how this occurs. Physical
association of Notch1 with other proteins such as PKCθ, the CBM and the IKK
complexes is mediated through the N-terminal region of N1ICD in the cytoplasm
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(Figures 3.5 and 3.8). We found that in the absence of Notch1, this molecular assembly
was abolished and the kinase activity of the IKK complex was decreased, leading to a
defect in IL-2 production.
Recent studies revealed that NICD exists as a monomer, thus, the structure of
NICD can be changed to an extended, linear molecule, a U-shaped, or a more compact
state depending on its conformation (Kelly et al., 2007). In addition, any factor
(potentially NF-κB) that can change the conformation of NICD may also regulate its
binding affinity to CSL. It is suggested that additional transcription factors may
associate with the nuclear complex containing NICD and CSL, leading to synergistic
cooperation to regulate the transcriptional activation of target genes. Previously, we
found the nuclear complex formation of Notch1 with NF-κB on the promoter of
downstream target genes, such as cyclin D3 and IFN-γ (Joshi et al., 2008; Shin et al.,
2006). Here, we further identified several downstream targets of Notch signaling in
which Notch1 forms a nuclear complex with p50 on the promoter, as described in
CHAPTER 2. The data from experiments performed in CHAPTER 4, suggest that CSL
is required for transcriptional activation of genes. Thus, the N1ICD complex, in
cooperation with NF-κB, regulates the transcriptional activity of the EOMES promoter
containing the region of SPS, which is designated for NF-κB and CSL binding motifs as
the head-to-head orientation with 17 nt spacing, and controlled by both NF-κB and
N1ICD. Using an in vitro reporter gene assay, we proposed that N1ICD/CSL associates
with NF-κBs on SPS to regulate transcriptional activation of Notch target gene
promoters, suggesting the different response of Notch target genes depends on the
cellular context or promoter context.
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It is worth while to investigate whether Notch1 is required for the formation of
highly ordered complexes, including NF-κB and CSL, and whether the promoter
containing proper binding order and space recruits this complex under physiological
conditions, among the purified full-length proteins. Biomolecules such as proteins fold
into thermodynamically stable structures, and this is crucial for their biological function.
To date, X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy
are the only experimental methods that routinely permit the determination of
macromolecular structures with atomic resolution (Habeck et al., 2005). Solving the
structure of such complexes with X-ray crystallography poses special challenges
because of their large size and the requirement for crystals with the requisite properties.
The method of multi-dimensional NMR is of benefit to high resolution three
dimensional (3D) structures of the protein, similar to what can be achieved by X-ray
crystallography. In contrast, NMR is primarily limited to relatively small proteins,
usually smaller than 35 kilodaltons (kDa). Both techniques require high purity and large
quantity of proteins for the fine structure of protein in solution and the technical
advances allowing determining large structures to be solved. Unlike traditional electron
microscopy (EM), which uses thin sections to visualize the structure of cells or tissues,
recently, advances have been made in methods and applications that determine the 3D
structure of individual proteins or protein complexes. EM can image complexes in their
physiological environment and does not require large quantities of the sample
(Henderson, 2004). Structures of macromolecular complexes with molecular weights
greater than 150 kDa can now be visualized in different functional states at intermediate
resolution (~5 to 15 Å). Blacklow and colleagues recently have shown that co-crystals
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of a human Notch transcriptional activation complex (NTC) core (Nam et al., 2006),
which consists of an N-terminal mastermind like-1 (MAML1) peptide, the ANK
domain of human Notch1, and CSL on a DNA duplex derived from the Hes1 promoter,
contain contacts between the convex surfaces of the ANK domains from adjacent unitcells that also are seen in crystals of the ANK domain solved in isolation in several
different crystallization conditions (Nam et al., 2006). In their recent report (Nam et al.,
2007), two NTC core contacts lie near a two-fold symmetry axis (~65 Å) in the crystals,
such that the interacting complexes are positioned head-to-head at a distance (~19 nt)
roughly equal to that needed to occupy both recognition elements of SPS and this
cooperative formation of dimeric Notch transcription complexes on a promoter with
paired sites is required to activate transcription. As well, they postulate that the
association with additional DNA-binding factor(s) may cooperate with NTC to activate
transcription of genes containing SPS. From the limited observation of macromolecular
complexes, NTCs, this approach using EM will demonstrate, under physiological
conditions, whether Notch1 is required for the formation of highly-ordered complexes,
including those containing NF-κB and CSL, and whether the promoter containing
proper binding order and space recruits these complexes or enhances the formation of
complexes containing N1ICD/CSL and NF-κBs. First, to address the question of
whether N1ICD and CSL form a nuclear complex with NF-κB, we need to obtain the
purified full-length proteins. The entire intracellular domain of Notch1 (amino acids
1759-2555), the entire CSL protein and two NF-κB subunits (p50 and c-Rel) should be
cloned into pFastBac HT B with sequences encoding a 6xHis tag at its N-terminus
(Figure 5.1), expressed in sf9 insect cells using a baculovirus over-expression system,
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lysed with the FastBreak™ Cell Lysis reagent and purified with the MagneHis™
Protein Purification System (Promega Co.) as followed by manufacturer’s protocols
(Figures 5.2-5.4). Single molecules of each protein or its oligomer complex with other
proteins; N1ICD+CSL, N1ICD+p50+c-Rel, N1ICD+CSL+p50+c-Rel, isolated from sf9
cells will be used for negative staining. Adequately stained single molecules or
complexes should be selected for single particle image processing, using a reference
free method (2D averaging technique (Burgess et al., 2004; Frank, 1996) and a
reference-based method (3D projection-matching technique (Penczek et al., 1994), and
imaged for additional structural details by 3D reconstruction on both EOMES DNA
fragments from ChIP assay.
Until now, we do not have direct evidence of interaction between N1ICD/CSL
and NF-κB. We have only observed direct interaction and nuclear complex formation
between Notch1 and NF-κB, but their interaction and requirement for promoter
regulation may differ with specific promoter contexts (CHAPTERS 2 and 4). Thus, it is
possible that N1ICD binds to CSL to form complexes that are separate from complexes
in which N1ICD binds to NF-κB, allowing competition between these groups for the
same DNA binding consensus motif (Shin et al., 2006; Wang et al., 2001). However, if
they share a binding motif on the promoter, one of the SPS may be occupied by NF-κB
to form a nuclear complex with N1ICD/CSL. If N1ICD/CSL fails to associate with NFκB, one factor which needs to be considered is the appropriate and sufficient formation
of the dimeric NF-κB complex of p50 and c-Rel, allowing appropriate association with
N1ICD/CSL in solution. As well, p65 may be a potential binding partner, instead of cRel, for the formation of the dimeric NF-κB complex with p50, as a classical model.
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Similarly, as described above, the purified proteins can be imaged with EOMES oligos
to examine whether the DNA fragment containing the binding motifs both of NF-κB
and CSL is required for the formation of the highly-ordered complex. The approach
proposed here will aid in determining whether pre-formation of the complex between
NTC and NF-κB is required for DNA binding at SPS on the promoter or whether each
complex binds their individual binding motifs and then form a tertiary complex
containing N1ICD/CSL and NF-κB in complex. The spacing between SPS sites on the
promoter may be a ciritical factor, driving an appropriate pre-complex formation as
suggested (Nam et al., 2007; Ong et al., 2006). This approach will help us to determine
whether a region containing similar SPS from different promoters, respond in a
dimerized complex dependent fashion.
In this body of work, I showed that N1ICD cooperates with NF-κB complexes
regulate the transcriptional activity of the EOMES promoter containing an SPS with 17
nt spacing for NF-κB and CSL binding sites. Nam et al. (2007) proposed the model, as
described above, by which two homo- or heterotypic complexes bind the region of
promoter with SPS and orientation using purified protein (truncated form) and asked
whether, in a test tube, the purified proteins bind a defined oligo as determined by
electrophoretic mobility shift assay (EMSA). However, the proteins which this group
used are not full length, except CSL, and are rather useful for co-crystallography. The
proteins purifed from sf9 insect cells, instead of E.coli cells, are more functional and
physiologically relevant. Although using nuclear extracts from cells in CSL-deficient
cells (OT11 cells) overexpressing the proteins of interest is the conventional strategy
used for EMSA assays, it may be that purified proteins will provide unequivocal data.
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Figure 5.1: Constructs for protein purification using baculoviral system
Each N1ICD, CSL and two NF-κB subunits (p50 and c-Rel) were subcloned into
pFastBac HT B after cutting by the restriction enzymes (red box, top). Each clone of
baculoviral constructs was confirmed first by treatment with the indicated restriction
enzymes (brown arrows) and then the chosen clones were checked by sequencing.
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Figure 5.2: Total scheme for protein expression (Invitrogen™) and purification
(Promega Co.)
Procedure for expression of each protein follows the Invitrogen™ system. To generate
recombinant bacmid DNAs, each baculoviral construct was transformed into bacmidproducing competent cells. Mini-prepped bacmid DNAs were used for protein
expression in sf9 insect cells. Final proteins were purified by magnetic bead-Ni column.
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Figure 5.3: Analyzing recombinant bacmid DNAs by PCR
Individual donor plasmids were used for generating each individual bacmid DNA. Each
insert from total bacmid was confirmed by PCR (blue arrows). For PCR, universial
M13 forward primer or M13 reverse primer was used with each available primer which
amplified ‘PCR product A’ (blue color) or ‘PCR product B’ (brown color).
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Figure 5.4: Isolating of baculoviral supernatants and testing of viral activity
To produce each protein, each bacmid DNA was transfected into sf9 insect cells. P1
baculoviral supernatants was used for production of high titer viral supernatants (P2 or
P3) and kept frozen at -70°C. The gels show protein expression by P3 viral supernatants.
N1ICD protein was detected by antibodies specific for Notch1, however, p50 and c-Rel
proteins were not as highly expressed.
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CHAPTER 6
MATERIALS AND METHODS

6.1 Materials
6.1.1 Mice
C57BL/6 and Notch1 AS mice were housed in the animal care facility at the
University of Massachusetts (Amherst, MA) in accordance with Institutional Animal
Care and Use Committee guidelines. Transgenic Notch1 AS mice originated from
backcrossing of C57BL/6H2B and SJLH2s with Notch1 AS transgene controlled by the
mouse mammary tumor virus long terminal repeat promoter (Cheng et al., 2001).
6.1.2 Cells
Total splenocytes or splenic CD8+ T cells (2-3 x 106 / ml) were from 8- to 12week-old mice. E.G7-OVA and EL4 cells were purchased from American Type Culture
Collection (ATCC CRL-2113 and ATCC TIB-39) and used for CTL functional assays.
The syngeneic tumor cell line of E.G7-OVA was constructed by transfecting the
parental EL4 cell line with cDNA expressing an MHC-class-I-restricted-peptide of
chicken ovalbumin, amino acids 258-276 (OVA258-276) (Moore et al., 1988). 293T cells
were used for testing constructs. Phoenix-Eco cells of retroviral packaging cell lines
were transfected for producing retroviral supernatants for the rescue experiments. Jurkat
T cell lines were used for human IL-2 ChIP analysis. OT11 cells kindly provided by Dr.
Tasuku Honjo (Koyto University, JAPAN) are the cell line of CSL-deficient embryonic
fibroblast compared with wild type, CSL-expressing OT13 cells. These were used for
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reporter gene assay. Spodoptera frugiperda sf9 insect cells were used for protein
expression by Bac-to-Bac® Baculovirus Expression System.
6.1.3 Media
Primary cells, 293T cells and Phoenix-Eco cells were cultured in 1:1 of DMEM
to RPMI 1640 (Invitrogen). Jurkat T cell lines, EL4 and E.G7-OVA cells were cultured
in RPMI 1640. Both OT11 and OT13 cells were cultured in DMEM. Fullysupplemented BaculoGold™ TNM-FH insect medium (BD Bioscience) was used for
sf9 cells. Serum free medium in retroviral transfection was OPTI-MEM (Invitrogen)
and unsupplemented Grace’s insect culture medium (Invitrogen) was used in
baculoviral transfection.
6.1.4 Plasmids and constructs
The retroviral empty vector pMX-IRES-hCD8 was kindly provided by Dr.
Yukiko Gotoh (JAPAN) and was used for the rescue experiments. pMX-N1ICD-IREShCD8 was generated by subcloning N1ICD from pcDNA-Notch1ICD constructs kindly
provided by Dr. Anthony Capobianco (The Wistar Institute, Philadelphia, PA) into
pMX-IRES-hCD8. EOMES cDNA in retroviral MigR1 vector was kindly provided by
Dr. Steven Reiner (University of Pennsylvania, Philadelphia, PA) and subcloned into
pMX-IRES-hCD8 for pMX-EOMES-IRES-hCD8. The EGFP-N1ICD deletion-NES
constructs

(Figure

3.6)

were

generated

by

replacing

N1ICDΔRAM/ΔANK/Δ2358/Δ2258 from EGFP-N1ICD mutants (Figure 3.3) into
N1ICD site of EGFP-N1ICD-NES. The plasmid of Carma1-vesicular stomatitis virus
(VSV) tag was previously described (Gaide et al., 2002). For producing lentiviral
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particles, pRRL U6 siRNA PGK puro SIN LTR containing siRNA sequence against for
Notch1 (pRRL-siNotch1), the vesicular stomatitis virus (VSV) envelope glycoprotein
(G protein) expression plasmid (pHCMV-G) and the packaging plasmid for HIV-1based vectors (pCMVΔR8.2) were kindly provided by Dr. Sheila A. Stewart
(Washington University School of Medicine, St Louis, MO). The EOMES reporter gene
was created with pGL3-promoter (Promega) after PCR and subcloning. Hes1 promoter
was kindly provided by Dr. Alain Israel and the reporter construct of NF-κBx3 luc was
from Clontech. For reporter gene assays, pcN1ICD as the Notch1ICD expression
construct, both pMT2T-p50 and pc-c-Rel as the NF-κB expression constructs, and
pcDNA3.1 HisC as the empty control were used. The internal control was pRL-CMV.
Constructs for protein purification were pFastBac HT B-N1ICD, pFastBac HT B-CSL,
pFastBac HT B-p50 and pFastBac HT B-c-Rel.
6.1.5 Antibodies
Mouse splenocytes or splenic CD8+ T cells were stimulated with anti-mouse
CD3ε and anti-mouse CD28 (BD Pharmingen) for indicated periods. Jurkat T cell lines
were stimulated with the anti-human CD3ε and anti-human CD28 antibodies from R&D
Systems. For ELISA, mouse IFN-γ with the paired capture and detection antibodies
(BD Pharmingen) were used with strep-avidin HRP (BD Pharmingen). Anti-EOMES
(Abcam), anti-Notch1 (Santa Cruz Biotechnology), anti-Notch1ICD (Cell Signaling
Technology), anti-T-bet (Santa Cruz Biotechnology), anti-FasL (Santa Cruz
Biotechnology),

anti-HSP70

(Affinity

BioReagents),

anti-GAPDH

(Chemicon

International) and ECL™ horseradish peroxidase linked whole secondary Ab (GE
Healthcare UK Limited) were used for immunoblotting. For cell surface staining, cells
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were stained with anti-mouse CD8a-PE, FITC or -allophycocyanin (BD Pharmingen™),
anti-mouse

CD4-FITC

(BD

Pharmingen™),

anti-mouse

CD25-FITC

(BD

Pharmingen™), anti-mouse CD44-FITC (BD Pharmingen™), anti-mouse CD69-FITC
(BD Pharmingen™) and compared with anti-mouse IgG1κ Isotype control FITC
(eBioScience). Anti-mouse CD178 (FasL)-PE (BD Pharmingen™) was tested with antihamster IgG1κ Isotype control PE (BD Pharmingen™). For intracellular staining, antimouse IFN-γ-PE (BD Pharmingen™) and anti-mouse/human Notch1-PE (eBioScience)
were compared with anti-mouse IgG1κ Isotype control PE (eBioScience). Anti-mouse
Perforin-PE or -FITC (eBioScience) was tested with anti-rat IgG2a Isotype control PE
or FITC (eBioScience) and anti-mouse/human Granzyme B-PE or -FITC (eBioScience)
was compared with anti-mouse IgG1κ Isotype control-PE (eBioScience). Antibodies
(rabbit anti-Notch1, rabbit anti-RBP-Jκ, goat anti-p50, rabbit anti-c-Rel, rabbit anti-p65,
normal rabbit IgG and normal goat IgG) for ChIP were from Santa Cruz Biotechnology.
Retroviral infection efficiency was monitored by anti-human CD8-PE (BD
Pharmingen™). For co-immunoprecipitation, monoclonal anti-VSV glycoprotein
antibody was purchased from Sigma-Aldrich and anti-GFP antibody was from Santa
Cruz Biotechnology.
6.1.6 Chemical reagents
Mouse CD8+ T cells were isolated from splenocytes by anti-mouse CD8a
particles-DM (BD IMag™). Cell culture reagents (fetal bovine serum (FBS),
gentamycin, penicillin, streptomycin, L-glutamine, β-mercapto ethanol and G418) were
purchased from Invitrogen and murine IFN-γ was from PeproTech Inc. Mouse IFN-γ
standard for ELISA was obtained from Roche. γ-secretase inhibitor, IL-CHO and LY-
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411,575 rodent chow were continuously provided by Dr. Abdul Fauq and IL-CHO was
dissolved in Dimethyl Sulphoxide (DMSO) from Sigma-Aldrich. RNA was isolated by
RNA-BEE (Tel-Test) and used for cDNA synthesis by DNase (Promega), Oligo dT
primers (Invitrogen™), dNTP nucleotide mixture (Roche), RNase inhibitor (Promega)
and M-MuLV Reverse Transcriptase (BioLabs). PCR was fulfilled by Platinum® PCR
Supermix (Invitogen™) and Q-PCR was performed by SYBR Green PCR Core
Reagens (PE Applied Biosystems). Both Protease Inhibitor Cocktails (Nolz et al., 2007)
and cell activation reagents (phorbol 12-myristate 3-acetate (PMA) and calcium
ionophore (CaI) were purchased from Sigma-Aldrich. As cell transfection reagent,
FuGENE® 6 was from Roche and polybrene was from Sigma-Aldrich. Monensin for
cell staining and Tween 20 were from Sigma-Aldrich. Paraformaldehyde for
intracellular staining was purchased from Fisher Scientific Company. Restore™
Western Blot Stripping Buffer was obtained from Thermo Scientific. Protein A- and Gsepharose beads were from Pharmacia Co. The transfection reagent for sf9 insect cells,
Cellfectin®, was from Invitrogen.
6.1.7 Commercial kits
BD OptEIA™ was from BD Bioscience Pharmingen. BCA Protein Assay Kit
was purchased from Pierce and ChIP Assay Kit was from Upstate Cell Signaling
Solutions. For DNA preparation or ChIP sample’s elution, Qiagen mini, midi, maxi
DNA preparation kits and Qiaquic spin kit from Qiagen were used. DELFIA EuTDA
Cytotoxicity Reagents Kit was obtained from PerkinElmer and Dual-Luciferase Assay
System was from Promega. For protein expression, bacmid DNAs were mini-preped by
high purified mini-prep kit (Invitrogen).

128

6.2 Methods
6.2.1 Primary cell isolation
To isolate splenocytes, spleens from 8- to 12-week-old mice were prepared in
fresh media (1:1 of DMEM to RPMI 1640, 10% FBS, 20 µg/ml gentamycin and 2 mM
L-glutamine) and ground by the flat end of the barrel from a sterile 10 ml syringe. The
cell suspensions were collected into 50 ml conical tubes with 10 ml of sterile 1xPBS
and centrifuged by 1000-1200 rpm for 5 min. After discarding the supernatants, cell
precipitations were pipetted with 5 ml ACK buffer (0.15 M NH4Cl, 10 mM KHCO3 and
0.1 mM Na2EDTA in distilled water (D.W.), then adjusted pH 7.2-7.4 by 1N HCl and
stored at room temperature (RT)) to destroy Red Blood Cells (RBC). After standing at
RT for 1 min, pellets were centrifuged at 1000-1200 rpm for 5 min, removed the
supernatants and resuspended in 3ml of media. Again, splenocytes were separated from
cell debris by filtering and used for experiments. CD8+ T cells were were isolated from
splenocytes using the IMag bead separation system (BD Pharmingen), following the
manufacture’s directions. Anti-mouse CD8a particles-DM (50 µl per 1 x107 cells) was
mixed with splenocytes. After rotating at 4°C, CD8+ T cells were separated by 3
consecutive incubations using the IMagnet in IMag buffer (0.5% BSA, 2 mM EDTA
and 0.09 or 0.1% NaNO3 in sterilized 1xPBS, then filtered and kept at 4°C) and used for
experiments.
6.2.2 Cell culture
Primary cells, 293T cells and Phoenix-Eco cells were cultured at 37°C with 5%
CO2 by fresh 1:1 medium of DMEM to RPMI 1640, 10% FBS, 20 µg/ml gentamycin
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and 2 mM L-glutamine. EL4 and E.G7-OVA cells were cultured at 37°C with 5% CO2
by RPMI 1640 supplemented with 10% FBS, 0.05 mM β-mercapto ethanol, 100 µg/ml
penicillin and streptomycin and 20 µg/ml gentamycin. 2 mM L-glutamine and 0.4
mg/ml G418 were added into the culture medium only for E.G7-OVA cells. Jurkat T
cells were cultured in RPMI 1640 containing 10% FBS, 10 µM β-mercaptoethanol, 100
µg/ml penicillin and streptomycin and 20 µg/ml gentamycin. Both OT11 and OT13 cell
lines were cultured at 37°C with 5% CO2 by DMEM, 10% FBS, 20 µg/ml gentamycin
and 2 mM L-glutamine. For these cells, 100 units/ml of murine IFN-γ was freshly added
into the culture medium before using. Fully-supplemented BaculoGold™ TNM-FH
insect medium (BD Bioscience) was used directly with 20 µg/ml gentamycin for sf9
cells in 27°C incubator.
6.2.3 GSI treatment
Generally, for using GSI in vitro, cells were pretreated for 30 min at 37oC with
50 µM IL-CHO, or DMSO as vehicle control, before stimulation. For in vivo GSI
experiments, LY-411,575 was formulated in rodent chow to deliver 5 mg/kg/day, based
on average consumption, and administered to mice for 13 days. However, for rescueexperiments, splenocytes were pretreated with 25 µM IL-CHO or DMSO, activated as
described as below, and retreated with 25 µM IL-CHO or DMSO before 2nd stimulation.
Treatment of antigen-specific stimulated cells is described in Effector Cell Preparation
under ‘Antigen-Specific CTL Functional Assay’).
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6.2.4 Activation of primary cells and cell lines
Both mouse splenocytes and splenic CD8+ T cells were activated to proliferate
with soluble anti-mouse CD3ε and anti-mouse CD28 (1 μg/ml each) for time periods
indicated in each of the figures. 80 nM PMA and 500 nM CaI were used for stimulating
cell lines or for 2nd stimulation of primary cells. For the stimulation of Jurkat T cell
lines, Ab-coated 60mm dishes were prepared. 20 µg/ml of anti-mouse IgG was
precoated at RT for 2 hr and then each 5 µg/ml of anti-human CD3ε and anti-human
CD28 antibodies were incubated at 4oC rocker for overnight. Jurkat T cells were seeded
in Ab-coated 60mm dishes and stimulated during 1 hr for ChIP assay.
6.2.5 Semiquantitative RT-PCR and quantitative Real-Time PCR (Q-PCR)
6.2.5.1 RNA extraction
Total RNA was isolated from CD8+ T cells, prepared as described above using
RNA-BEE (Tel-Test), following the manufacture’s directions. Harvested cells were
washed in 1ml 1xPBS and the pellets were resuspended in 1 ml RNA-BEE. 200 µl
Choloroform was added into the mixture and vortexed vigorously for 30 sec. After
centrifugation at 4oC at 14000 rpm for 20 min, the aqueous fraction was carefully
harvested into new tube and 600 µl Isopropanol was added. The mixture was mixed
lightly and centrifuged at 4oC at 14000 rpm for 20 min. RNA pellet was washed in 500
µl of 70% Ethanol-DEPC·H2O, dried by vaccum for 5 min and resuspended in 50 µl
DEPC·H2O. Extracted RNA was quantified by optical density (O.D.) value at 260 nm
before using.
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6.2.5.2 Semiquantitative RT-PCR
After DNase treatment (Promega), reverse transcription of 1-2 µg RNA was
performed with Oligo dT primers (Invitrogen™), and cDNAs were analyzed by semiquantitative PCR or Q-PCR. For semi-quantitative PCR, three different cycles described
below were tested and PCR reactions were performed with the following primers:
EOMES forward: 5΄-ATG CAG TTG GGA GAG CAG CTC CTG-3΄; reverse: 5΄-GTT
GCA CAG GTA GAC GTG-3΄; Perforin forward: 5΄-CAA GCA GAA GCA CAA GTT
CGT-3΄; reverse: 5΄-CGT GAT AAA GTG CGT GCC ATA-3΄; Granzyme B forward:
5΄-ACT TTC GAT CAA GGA TCA GCA-3΄; reverse: 5΄-ACT GTC AGC TCA ACC
TCT TGT-3΄; GAPDH forward: 5΄-ACT TTC GAT CAA GGA TCA GCA-3΄; reverse:
5΄-ACG GAA GGC CAT GCC AGT GAG CTT-3΄. Conditions: the shortest cycle:
94°C 2 min, 94°C 30 sec, 55°C 30 sec, 68°C 30 sec (20 cycles), no extension; the
optimal cycle: 94°C 2 min, 94°C 30 sec, 55°C 30 sec, 68°C 30 sec (25 cycles), 68°C 5
min; the longest cycle: 94°C 2 min, 94°C 30 sec, 55°C 30 sec, 68°C 30 sec (30 cycles),
68°C 5 min. The machine used was Mastercycler gradient from Eppendorf.
6.2.5.3 Q-PCR
First, semi-quantitative PCR products of perforin and granzyme B were
subcloned into pCR2.1 (Invitrogen™) as cDNA control plasmids. Specific primers from
Primer Bank of CCIB (the Center for Computational and Integrative Biology in Harvard
Medical School) were used: Perforin (PrimerBank ID 6755042a3) forward: 5΄-GCT
CCC ACT CCA AGG TAG C-3΄; reverse: 5΄-TTT GTA CCA GGC GAA AAC TGT3΄; Granzyme B (PrimerBank ID 7305123a3) forward: 5΄-TGC TGC TAA AGC TGA
AGA GTA AG-3΄; reverse: 5΄-CGT GTT TGA GTA TTT GCC CAT TG-3΄. The

132

control plasmids of each target sequence were diluted to generate standard curves. Realtime quantitative PCR amplification was performed on a Bio-Rad iCycler by using
SYBR Green PCR Core Reagents (PE Applied Biosystems, Foster City, CA). To
quantify the amount of cDNA for an individual transcript, SYBR Green fluorescence
was measured at the end of each cycle. The cycle threshold (Ct), the cycle at which
exponential growth of the PCR product was first detected, was determined for known
concentrations of plasmid DNA (pCR2.1 Perforin, pCR2.1 Granzyme B and pGEM 18s
ribosomal RNA), and then a standard curve was created. Template copy numbers were
calculated for each sample by interpolating the Ct values on the standard curve, using
the iCycler software. All samples and standards were run in triplicate for any given
experiment. The values of perforin and granzyme B were normalized to 18s rRNA as
the average copy number. Specific products were verified by melt-curve analysis and
gel electrophoresis. Q-PCR conditions: the first cycle; 95°C 8 min 30 sec, the second
cycle; 95°C 30 sec, 53°C 30 sec, 72°C 30 sec (40 cycles), the third cycle; 95°C 1 min,
the fourth cycle; 53°C 10 sec and increase temperature after cycle 2 by 0.5°C (80
cycles) for collecting melt curve data. Specific primers for 18s rRNA: forward: 5’-TGG
TGG AGC GAT TTG TCT GG-3’; reverse: 5’-TCA ATC TCG GGT GGC TGA AC-3’.
6.2.6 Enzyme-linked immunosorbant assay (ELISA)
The supernatants from 2x106 CD8+ T cells prepared as described above were
harvested after incubation at 37°C for times indicated and analyzed by standard ELISA
techniques for the secretion of IFN-γ with the paired capture and detection antibodies.
IMMPLATE Maxisorp plates (Fisher) were coated with 100 µl of mouse IFN-γ capture
Ab (1:500) in 0.1M phosphate buffer (0.1 M Na2HPO4, pH 9.0) at 4oC overnight. The
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next day, coated wells were washed 3 times with 200 µl of 0.05% Tween 20 in 1xPBS
and blocked with 200 µl of 10% FBS in 1xPBS at RT for 2-3 hr. Mouse IFN-γ standard
was diluted to 156.25, 312.5, 625, 1250, 2500, 5000 and 10000 pg/ml and 100 μl of the
culture supernatants and standards were applied to the prepared plate. After incubation
at 4oC overnight, the plate was washed 6 times with 200 µl of 0.05% Tween 20 in
1xPBS. For detection, 100 μl of biotinylated rat anti-mouse IFN-γ (1:1000) and strephorseradish peroxidase-labeled avidin (1:1000) were added to each well and incubated
at RT for 1 hr. Then, each well was washed 6 times with 200 µl of 0.05% Tween 20 in
1xPBS. The color reaction was developed with 100 μl of substrate mix (1:1 of substrate
reagents A and B) for 2-10 min and stopped by the addition of 50 μl of 2N H2SO4. The
O.D. of each well was estimated at 450 nm using an MRX microplate reader (Dynex
Technologies) and the secreted levels of IFN-γ were calculated based on a standard
curve of known concentrations of IFN-γ standard.
6.2.7 Immunoblotting analysis
6.2.7.1 Protein lysis and quantification
The cell pellet was resuspended in 40-100 µl RIPA lysis buffer (1% NP 40, 10
mM Tris (pH 7.6), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate and 2 mM EDTA)
with protease inhibitor cocktail (1.25 µl PIC/1ml RIPA buffer). During incubation on
ice for 10 min, the cell resuspension was vortexed every 2-3 min. After centrifugation at
4oC at 14000 rpm for 10 min, the supernatant was harvested into a new tube. For protein
quantification, BCA assay was used. Bovine Serum Albumin (BSA) standard was
diluted to 50, 100, 200, 400, 600, 800 and 1000 µg/ml and each lysate was diluted 1:10
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using distilled water. Each 25 µl standard and lysate was applied to the appropriate
wells and 200 µl of BCA working reagents were added into each well. The plate (Flat
bottom assay plate, Costar) was incubated at 37oC for 30-60 min, O.D. was read at 562
nm using the MRX microplate reader (Dynex Technologies) and each concentration of
protein lysates were calculated based on a standard curve of known concentrations of
BSA.
6.2.7.2 Western blot
25 µg protein was mixed with an equal volume of 2x Laemmli sample buffer
(4% SDS, 200 mM DTT, 120 mM Tris-HCl (pH 6.8), 50% glycerol, and 0.02%
bromophenol blue) and loaded in lanes of 6-12% SDS-PAGE gel for analysis by
immunoblotting. Proteins resolved on the gel were transferred to PVDF membrane
(Immobilon-P Transfer Membrane, MILLIPORE) using a current of 100 volts for 1.5 hr
as per manufacturer’s instructions (Biorad). The membranes were blocked with 5%
skim milk (0.05% Tween 20 in 1xPBS) for >20 min at RT. Then the membranes were
incubated at 4oC overnight with the primary antibody diluted in 5% skim milk. Next
day, membranes were washed 3 times by 0.05% Tween 20 in 1xPBS every 10 min and
incubated at RT with ECL™ horseradish peroxidase labeled secondary Ab diluted in
5% skim milk for 1.5 hr. The membranes were washed 3 times using 0.05% Tween 20
in 1xPBS for 10 min each, developed by enhanced chemiluminescence (Amersham
Biosciences) as per the manufacturer’s instructions and exposed to RX-B Blue X-Ray
Film (Krackeler). Sequentially-stripped blots were reprobed with various antibodies.

135

6.2.8 Retroviral infection
6.2.8.1 Preparation of DNA constructs
N1ICD construct was generated by subcloning into pMX-IRES-hCD8 vector
into BamHI and SalI sites for retroviral infection (pMX-N1ICD-IRES-hCD8). EOMES
cDNA was also subcloned into EcoRI and XhoI sites of pMX-IRES-hCD8 vector for
retroviral infection (pMX-EOMES-IRES-hCD8). All constructs were confirmed by
sequencing and by western blot in over-expressing into 293T cells.
6.2.8.2 Production of retroviral particles and retroviral infection
One day prior to transfection, Phoenix-Eco cells (2x105/ml), used for producing
retroviral particles in the supernatants, were cultured with fresh media, in 100mm
culture dishes. Next day, after changing the media of Phoenix-Eco cells, 4 µg each of
DNA construct (N1ICD and EOMES in pMX-IRES-hCD8 vector or pMX-IRES-hCD8
empty vector) were incubated at RT with 12 µl FuGENE® 6 and OPTI-MEM (final to
be 200 µl) for 30 min and then added to Phoenix-Eco cells. Retroviral supernatants
were collected after 3 days, filtered through 0.45 µm syringe filter (Nalgene) and added
to CD8+ T cells isolated from splenocytes and stimulated for 1 day. Infected cells were
cultured at 37°C with 5% CO2 for 3 days. Infection efficiency was monitored by hCD8+
expression, using an LSRII flow cytometer and DIVA software (BD Immunocytometry
Systems).
6.2.9 Cell surface staining and intracellular staining
1-1.5x107 splenocytes or CD8+ cells were treated with monensin. 4 µl monensin
per 1 ml cells (2 mM monensin stock by 100% ethanol was used) was added and cells
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were further incubated at 37°C for 2 hr before harvest. For cell surface co-staining, cells
were washed with 200 µl 1xPBS, resuspended in 50 µl FACS staining buffer (FSB: 4%
heat inactivated FBS plus 0.02% Na-Azide in 1xPBS) with 1 µl Ab for cell-surface
protein and incubated at 4°C for 30 min, with protection from the light. Otherwise, after
collecting into 1.5 ml eppendorf tube and washing with 200 µl FACS wash buffer
(FWB: 2 mM EDTA plus 0.02% Na-Azide in 99.4 ml 1xPBS), the cells were fixed with
200 µl of 2% paraformaldehyde (PFA; 7.4% stock (pH 7.4) kept at -70°C was freshly
diluted by 1xPBS) for 15 min at RT, protected from the light. Fixed cells were washed
one time with 200 µl FWB or 1xPBS and then permeabilized at 4°C with 200 µl
permeabilization buffer (PB: 0.1% saponin plus 20% heat inactivated FBS plus 0.02%
Na-Azide in 6.98 ml 1xPBS). After 3-4 hr, cells were washed one time with 200 µl
permeabilization wash buffer (PWB: 0.1% saponin plus 0.1% Na-Azide in 17.8 ml
1xPBS) and resuspended in 50 µl permeabilization staining buffer (PSB: 0.2% saponin
plus 4% heat inactivated FBS plus 0.1% Na-Azide in 7.5 ml 1xPBS). For FACS
analysis of intracellular staining, a minimum of 1x106 CD8 cells were stained with 1 µl
Ab at 4°C for 30 min with protection from light and resuspended in 200 µl 1xPBS, after
washing 2 times with 200 µl PWB. Cells were then fixed in 200 µl PFA for 15 min at
RT and washed one time with 200 µl FWB. Flow cytometry was performed using a
FACSCalibur, and analyzed using CellQuest or FLOWJO software. Unstimulated and
unstained CD8 cells used as negative controls were prepared every time. For
intracellular staining, PB, PSB and PWB as well as saponin stock were freshly prepared
just before using.
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6.2.10 Chromatin immunoprecipitation (ChIP) assay
6.2.10.1 ChIP on mouse EOMES, perforin and granzyme B promoters
ChIP analysis was performed using 1x106 CD8+ T cells from GSI- or DMSOpretreated splenocytes stimulated for 1 day, as describe above, and using the ChIP
Assay Kit, following the manufacturer’s instruction. 10 ml of cells were treated with
270 µl of 37% formaldehyde for 10 min at RT to cross-link chromatin. Cells were
washed 2 times with cold 1xPBS and centrifuged at 4°C at 2000 rpm for 4 min. The
pellet of 1x106 CD8+ T cells was resuspended in 200 µl SDS Lysis Buffer included PIC
(1 µl/800 µl reaction) and incubated on ice for 10 min. DNA was sheared by 3
replications of 10 sec sonication interspersed with 1 min standing on ice. After
centrifugation at 4°C at 13000 rpm for 10 min, 200 µl supernatant was transferred into
new 2 ml tube and diluted with 1.5 ml ChIP Dilution Buffer including 2 µl PIC, except
input control. A total of 2 ml of supernatant was precleared with 80 µl protein Asepharose beads, which had been washed 3 times with lysis buffer, at 4°C, with rotating,
for 1 hr. After centrifugation at 4°C at 2500 rpm for 1 min, the harvested supernatants
were incubated with each Ab (4 µg/point of samples) overnight at 4°C. Next day, 60 µl
of Salmon Sperm DNA/Protein A Agarose Slurry was added into each vial and
incubated at 4°C, with rotating, for 1 hr. After gentle centrifugation at 4°C at 1000 rpm
for 1 min, the supernatant was removed carefully and the pellet-agarose was washed 4
times with various Wash Buffers according to the manufacturer’s protocol. DNAprotein-bead complexes were resuspended in 250 µl fresh elution buffer (1% SDS, 0.1
M NaHCO3) and incubated at RT for 15 min with rotation. Reverse-cross-linking of
DNA was performed by adding 20 µl 5 M NaCl (8 µl for 200 µl input control) and
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heating at 65°C for 4 hr. The de-cross-linked DNA was eluted by gel extraction
columns (Quiaquic Spin Kit, Qiagen), according to the manufacturer’s protocol. 600 µl
QG buffer (Qiagen) and 200 µl isopropanol were added into 500 µl sample reaction. If
the color of the mixture turned from yellow to purple after mixing, the sample needed to
be mixed with 10 µl of 3 M NaAcetate (pH 5.2). The 700 µl mixture was loaded into
the purple column and spun down 2 times at 14000 rpm for 1 min. The column was
washed 1 time with 500 µl QG buffer, spun at 14000 rpm for 2 min and, then washed 2
times with 700 µl PE buffer (Qiagen) and spun at 14000 rpm for 2 min. DNA was
eluted from the column with 60 µl EB buffer (Qiagen) and spun at 14000 rpm for 2 min.
The DNA eluates were detected by PCR with primers specific for each promoter. The
following primers were used for PCR: mouse EOMES primer Set1 (472 bp) forward:
5΄-AGT TTC CCG TGT GAT CGC ATT GG-3΄; Set1 reverse: 5΄-AGG CCG TCA
CTT TCA TTA CTC AG-3΄; Set2 (369 bp) forward: 5΄-GGT AGA CCA TGT TCG
CAG ACT TCA-3΄; Set2 reverse: 5΄-CAT TTA GCA ACC AGC CAT TTC CTC-3΄;
mouse perforin primer forward: 5΄-CTC AGA AGC AGG GAG CAG TC-3΄; reverse:
5΄-TGC GAT CTA TCC CCA GGC AG-3΄; mouse granzyme B primer forward: 5΄AGC TTG GGT TTC TGG GAC TCT GA-3΄; reverse: 5΄-TAT GAA AAC TCC TGC
CCT ACT GCC-3΄. Antibodies: rabbit anti-Notch1, rabbit anti-RBP-Jκ, goat anti-p50,
normal rabbit IgG and normal goat IgG. Conditions: 94°C 2 min, 94°C 30 sec, 55°C 30
sec, 68°C 30 sec (35 cycles), 68°C 5 min.

139

6.2.10.2 ChIP on human il-2 promoter
6.2.10.2.1 Production of lentiviral particle and lentiviral infection
One day prior to transfection, 293T cells (3x106/ml), used for producing
lentiviral particles in the supernatants, were cultured with fresh media in 100mm culture
dishes. Next day, after changing the media of 293T cells, 12 µg each of DNA construct
(6 µg pRRL-siNotch1, 3 µg pHCMV-G and 3 µg pCMVΔR8.2) were incubated at RT
with 12 µl FuGENE® 6 and OPTI-MEM (final to be 100 µl) for 30 min and then added
to 293T cells. The transfection mixture was mixed with 1 ml complete culture medium
and then transferred into 293T cells. One day after adding DNA-transfection mixture
into 293T cells, the cultured medium was replaced with fresh medium. Lentiviral
supernatants were collected 2 days later and filtered through 0.4 µm syringe filter.
Meanwhile, Jurkat T cells (1x107/ml) were also plated in 100mm dishes for lentiviral
infection and then mixed well with 10 ml of the filtered lentiviral culture supernatant
plus 10 µg/ml polybrene. After 1 day of infection, 20 ml of fresh RPMI complete media
was added to the cell cultures with lentiviral supernatant and selected at 37°C with 5%
CO2 for 3 days post-infection. Successful reduction of endogenous expression of
Notch1 was monitored by immunoblotting.
6.2.10.2.2 ChIP
2x106 Jurkat T cells were stimulated with plate-bound anti-hCD3ε and antihCD28 antibodies for 1 hr as describe above. The kits, reagents and conditions used
were identical to those of the murine promoter assays. For PCR, 5 μl from a 50 μl DNA
extraction and 30 cycles of amplification were used. To target three regions, three sets
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of primers based on NF-κB consensus binding motif, except the primers for Region B
described in Figure 3.10, were tested. The primer set for Region A forward: 5΄-CCA
CCC CCT TAA AGA AAG GA-3΄; reverse: 5΄- ATT GTG GCA GGA GTT GAG GT3΄; Region B forward: 5΄- TCA AGT GTC CCC AGG TTA AA-3΄; reverse: 5΄- TTT
TTA AAG GGT GCG ATT GTT-3΄; Region C forward: 5΄-TCA AAT ACC TCA TTG
GAA AAG C-3΄; reverse: 5΄-GCG TTA GGT AAT GTT CGG AGA-3΄. Antibodies:
goat anti-p50, rabbit anti-c-Rel, rabbit anti-p65, normal goat IgG and normal rabbit IgG.
Conditions: 95oC for 2 min, 95oC for 30 sec, 53oC for 30 sec, 72oC for 30 sec (30
cycles), 72oC for 5 min.
6.2.11 Ag-specific CTL functional assay
6.2.11.1 Effector cells preparation
For CTL priming, C57BL/6 mice were immunized with 5x106 E.G7-OVA (or
EL4 as control) cells/500 µl 1xPBS to generate H2Kb-restricted cytotoxic lymphocytes
specific for the OVA258-276 peptide and then, after 16 days, splenocytes were harvested
and pretreated in vitro for 30 min at 37°C with 25 µM IL-CHO, or with DMSO as
control. However, for the experiment with GSI in vivo, LY-411,575 delivered in rodent
chow (5 mg/kg/day) had been orally administered to C57BL/6 mice for a total 19 days,
beginning 3 days before priming and continuing until splenocytes were harvested 16
days later. Primed splenocytes with GSI treatment were cultured with the γ-irradiated
1.5x106 E.G7-OVA or EL4 cells (30000 rad) for stimulation. After 5 days, CD8+ cells
were harvested and isolated as previously described. Live cells were counted based on
trypan blue exclusion using a hematocytometer.
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6.2.11.2 Target cells labelling
1x106 each of E.G7-OVA and EL4 cells were washed 1 time with 1xPBS and
resuspended in 2 ml media. 5 µl of warmed, fluorescence enhancing ligand, BATDA,
was added and incubated for 20-30 min at 37°C. After carefully spinning down, the
cells were washed 3 times with 1xPBS and prepared at a concentration of 5x104/ml in
fresh media.
6.2.11.3 Cytotoxicity assay
The assay was performed using DELFIA® EuTDA cytotoxicity reagents
AD0116 based on fluorescence enhancing ligand and time-resolved fluorimeter
(SpectraMax M5 plus SOFTmax PRO) in black flat-bottom plates (Costar) following
the manufacturer’s instructions. CD8+ T cells were prepared with an equal number of
CD8 depleted cells as effector cells and 5000 E.G7-OVA or EL4 cells were used as
target cells. First, 100 µl of the labeled target cells (5x104/ml) was seeded in a roundbottom sterile plate and then CD8+ T cells were loaded into the plate based on the ratios
of effector cells (E):target cells (T) which were 40:1, 20:1 10:1 and 1:1. After 2 hr
incubation at 37°C with 5% CO2, 20 µl of the supernatant was transferred into a black
flat-bottom plate and mixed with 200 µl of Europium solution. Reaction time was 15
min at RT. And the fluorescent and chelated (EuTDA) products were generated by 15
min incubation at RT and were measured by time-resolved fluorimeter at an excitation
wavelength of 320-340 nm and emission wavelength of 610 nm. Specific release (%)
was calculated using the manufacturer’s equation.
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6.2.12 Co-immunoprecipitation (Co-IP) assay
6.2.12.1 Preparation of DNA constructs
Four EGFP-N1ICD deletion-NES constructs (EGFP-N1ICDΔRAM-NES,
EGFP-N1ICDΔANK-NES, EGFP-N1ICDΔ2358-NES and EGFP-N1ICDΔ2202-NES)
were created by subcloning each N1ICD-deletion sequence into N1ICD site of EGFPN1ICD-NES. N1ICDΔRAM by SmaI, N1ICDΔANK by ApaI, N1ICDΔ2358 by BamHI
and SalI and N1ICDΔ2202 by SacII were subcloned into the restriction enzyme sites of
EGFP-N1ICD-NES after deleting N1IC. All constructs were confirmed by GFP
expression in 293T cells and by western blot.
6.2.12.2 Co-IP
One day before transfection, 293T cells (2x105/ml) were freshly prepared. The
following day, 293T cells were transfected with indicated plasmids using FuGENE® 6.
After 2 days, cells were washed 2 times with 1 ml 1xPBS and lysed for 30 min at 4oC in
500 µl of 1% NP-40 lysis buffer (10 mM Tris-HCl pH 7.8, 0.5 mM EDTA, 250 mM
NaCl) with protease inhibitor cocktail (8 µl/ml). After centrifugation at 4oC at 14000
rpm for 10 min, 50 µl of supernatants was kept at 4oC and the rest was precleared with
500 µl of normal serum and 80 µl of protein A- or G-sepharose beads at 4oC, with
rotating, for 1 hr. Beads were washed 3 times with 1% NP-40 lysis buffer before using.
After centrifugation at 4oC at 2000 rpm for 5 min, the precleared supernatants were
incubated at 4oC, with rotating, overnight with 2-4 µg of each Ab. Next day, only IP
samples were mixed 80 µl of protein A- or G-sepharose beads and incubated at 4oC,
with rotating, for 1 hr. After centrifugation at 4oC at 3000 rpm for 2 min, the

143

supernatants were roughly discarded. Again, the mixture was washed with 1 ml of of
1% NP-40 lysis buffer with protease inhibitor cocktail up to 4 times. Following the final
wash, IP samples were resuspended in 60 µl 2x Laemmli sample buffer and boiled for 5
min. For immunoblotting, 10 µl input control was mixed with 10 µl 2x Laemmli sample
buffer and all samples were resolved by SDS-PAGE, then visualized using anti-VSV
and anti-GFP antibody.
6.2.13 Dual-luciferase reporter gene assay
1x106 293T, OT11 and OT13 cells were plated in individual 60 mm dishes and
transfected with the indicated expression construct or empty vector control. Each 0.4 μg
reporter constructs of pGL3-EOMES, Hes1 promoter and NF-κBx3 luc premixed 0.1 μg
pRL-CMV as internal control mixed pcN1ICD and/or pMT2T-p50 and pc-c-Rel with
pcDNA3.1 HisC as empty control up to 1.5 µg. When the increasing amounts of some
construct were needed, each amount added was determined by the ratio against the
plasmids. Transfection was performed with 12 µl FuGENE® 6 and OPTI-MEM media
for 100 µl volume, then Luciferase assays were performed 2 days after transfection,
following the manufacturer’s instructions. Harvested cells were gently washed 1 time
with 1xPBS and incubated with 500 µl 1xPassive Lysis Buffer at RT for 30 min. After
centrifugation at 4°C at 14000 rpm for 5 min, a total of 400 µl of supernatant was
harvested and 10 µl of the supernatant was assayed. Luciferase values were detected
using a TD-20/20 Luminometer (TURNER DESIGNS). Each firefly luciferase value
was normalized against each renilla luciferase activity.
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6.2.14 GFP microscopy
GFP expression by EGFP-truncated N1ICD constructs were examined by
confocal microscopy (LSM510, Carl Zeiss) or fluorescent microscopy (Diaphot TMD,
Nikon). The 293T cells transfected with indicated plasmids were examined for GFP
expression using laser-scanning confocal microscopy with a 40x phase contrast oil
immersion objective (numerical aperture=1.3) or fluorescent microscopy with a green
fluorescent filter. For confocal microscopy, excitation of EGFP was performed using an
Argon ion laser at 488 nm and emitted light was reflected through a 505-530 nm
bandpass filter from a 540 nm dichroic mirror. Confocal data capture and extraction
were performed using manufacturer’s software (Zeiss LSM Image Browser version 3.1).
6.2.15 Protein Expression
6.2.15.1 Cloning the baculoviral constructs
Each N1ICD, CBF-1 and two NF-κB subunits (p50 and c-Rel) were subcloned
into pFastBac HT B after cutting by restriction enzymes (Figure 5.1), then used to
transform DH5α competent cells. 10-15 clones of each baculoviral construct were
confirmed by digesting with specific restriction enzymes and then checking the size of
the digested gragment. N1ICD: ≈ 2.3 kb by BamHI and XhoI; CSL (marked in figures
by CBF-1): ≈ 1.5 kb by BamHI or 660 bp and 809 bp by BamHI and EcoRI; p50: by
HindIII; c-Rel: by HindIII. Then the clones which were shown to have the right sizes
were checked for the orientation of the inserts by sequencing.
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6.2.15.2 Generation of bacmid DNAs
Following the Invitrogen™ protocol (Figure 5.2), recombinant bacmid DNA
was generated using the bacmid-producing competent cells. Each construct in pFastBac
HT B vector was transformed using MAX Efficiency®DH10Bac™ cells (Invitrogen) in
LB plates containing selection markers (50 µg/ml kanamycin, 7 µg/ml gentamicin, 10
µg/ml tetracycline, 100 µg/ml Bluo-gal and 40 µg/ml IPTG) and mini-prepped by high
purification mini-prep kit (Invitrogen). The inserts in the bacmids were confirmed by
PCR. For PCR, either universal M13 forward primer or M13 reverse primer
(Invitrogen) was used with each available primer which recognized 5΄- or 3΄-terminus
of each insert (Figure 5.3). Conditions: 93oC for 3 min, 94oC for 45 sec, 55oC for 45 sec,
72oC for 5 min (35 cycles), 72oC for 7 min.
6.2.15.3 Production of baculoviral supernatants
Bacmid DNA was transfected into sf9 insect cells using Cellfectin®
transfection reagent. At least 1 hr before transfection, sf9 cells (9x105/2 ml) were
prepared in 6 well-plates. Meanwhile, 6 µl of Cellfectin® transfection reagent and 13 or
26 µl of each bacmid DNA was mixed in 100 µl of Grace media and then incubated at
RT for 30 min. 1 hr later, just before adding bacmid DNA:lipid complexes, the sf9 cells
were washed 1 time with 2 ml Grace media and resuspended in about 0.5 ml of Grace
medium. Meanshile, 0.2 ml of bacmid DNA:lipid mixtures and 0.8 ml Grace medium
were mixed well by pipetting and added to each well containing cells. The cells were
incubated at 27°C for 5 hr and, then, further cultured with 2 ml of complete growth
media after removing DNA:lipid complexes. Cell status at 27°C was checked everyday,
up to 3 days post-infection. On the 3rd day, 1 ml of P1 viral supernatants was harvested
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and filtered through 0.45 µm syringe fillter (NALGENE®) and 0.5 ml of culture media
was added for further culture. P2 or P3 viral supernatants were produced by re-infection
with 400 µl of P1 supernatant or previous viral supernatants. The rest of the baculoviral
supernatants were kept at -70°C until use. Successful protein expression with each viral
supernatant was monitored by immunoblotting. For actual protein expression, the
supernatants with the highest titers were used.
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